WO2006008653A9 - Lipolytic enzyme uses thereof in the food industry - Google Patents
Lipolytic enzyme uses thereof in the food industryInfo
- Publication number
- WO2006008653A9 WO2006008653A9 PCT/IB2005/002602 IB2005002602W WO2006008653A9 WO 2006008653 A9 WO2006008653 A9 WO 2006008653A9 IB 2005002602 W IB2005002602 W IB 2005002602W WO 2006008653 A9 WO2006008653 A9 WO 2006008653A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lipolytic enzyme
- enzyme
- amino acid
- seq
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B3/00—Refining fats or fatty oils
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
- A21D8/00—Methods for preparing or baking dough
- A21D8/02—Methods for preparing dough; Treating dough prior to baking
- A21D8/04—Methods for preparing dough; Treating dough prior to baking treating dough with microorganisms or enzymes
- A21D8/042—Methods for preparing dough; Treating dough prior to baking treating dough with microorganisms or enzymes with enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J7/00—Phosphatide compositions for foodstuffs, e.g. lecithin
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B3/00—Refining fats or fatty oils
- C11B3/003—Refining fats or fatty oils by enzymes or microorganisms, living or dead
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11C—FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM
- C11C3/00—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
- C12N9/20—Triglyceride splitting, e.g. by means of lipase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6409—Fatty acids
- C12P7/6418—Fatty acids by hydrolysis of fatty acid esters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6436—Fatty acid esters
- C12P7/6445—Glycerides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6436—Fatty acid esters
- C12P7/6445—Glycerides
- C12P7/6481—Phosphoglycerides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/01—Carboxylic ester hydrolases (3.1.1)
- C12Y301/01003—Triacylglycerol lipase (3.1.1.3)
Definitions
- the present invention relates to a novel lipolytic enzyme, in particular a novel lipolytic enzyme, and nucleotide sequences encoding same.
- the present invention also relates to methods of production of the novel lipolytic enzyme and to uses thereof.
- the present invention also relates to methods and uses of a lipolytic enzyme.
- a lipolytic enzyme from Fusarium oxysporum having phospholipase activity has been taught in EP 0 869 167. This lipolytic enzyme has high triacylglyceride hydrolysing (lipase) activity. This enzyme is now sold by Novozymes A/S (Denmark) as Lipopan FTM.
- WO02/00852 discloses five lipase enzymes and their encoding polynucleotides, isolated from Fusarium venenatum, F. sulphureum, Aspergillus berkeleyanum, F. culmorum and F. solani. AU five enzymes are described as having triacylglycerol hydrolysing activity, phospholipase and galactolipase activity.
- Lipolytic enzyme variants with specific amino acid substitutions and fusions, have been produced; some of which have an enhanced activity on the polar lipids compared to the wildtype parent enzymes.
- WO01/39602 describes such a variant, referred to as SP979, which is a fusion of the Thermomyces lanuginosus lipase, and the Fusarium oxysporum lipase described in EP 0 869 167. This variant has been found to have a significantly high ratio of activity on phospholipids and glycolipids compared to triglycerides.
- the present invention in predicated upon the seminal finding of a lipolytic enzyme having significant galactolipid activity from the genus Streptomyces.
- the lipolytic enzyme from the genus Streptomyces has significant galactolipid hydrolysing activity and/or significant galactolipid acyltransferase activity, particularly when used in the methods and uses according to the present invention.
- the present invention in predicated upon the seminal finding that lipolytic enzymes from the genera ⁇ iermobifida or Corynebacterium have significant galactolipid activity.
- the lipolytic enzymes from the genera Thermobifida or Corynebacterium have significant galactolipid hydrolysing activity and/or significant galactolipid acyltransferase activity, particularly when used in the methods and uses of the present invention.
- the present invention relates to a lipolytic enzyme capable of hydrolysing at least glycolipids and/or capable of transferring an acyl group from at least a glycolipid to one or more acyl acceptor substrates, wherein the enzyme is obtainable, preferably obtained, from Streptomyces species.
- the present invention relates to a lipolytic enzyme capable of hydrolysing at least galactolipids and/or capable of transferring an acyl group from at least a galactolipid to one or more acyl acceptor substrates, wherein the enzyme is encoded by a nucleic acid selected from the group consisting of: a) a nucleic acid comprising a nucleotide sequence shown in SEQ DD No. 3; b) a nucleic acid which is related to the nucleotide sequence of SEQ ID No. 3 by the degeneration of the genetic code; and c) a nucleic acid comprising a nucleotide sequence which has at least 70% identity with the nucleotide sequence shown in SEQ ID No. 3.
- a nucleic acid selected from the group consisting of: a) a nucleic acid comprising a nucleotide sequence shown in SEQ DD No. 3; b) a nucleic acid which is related to the nucleotide sequence of S
- the present invention yet further provides a lipolytic enzyme comprising an amino acid sequence as shown in SEQ ID No. 4 or an amino acid sequence which has at least 60% identity thereto.
- the present invention provides a lipolytic enzyme capable of hydrolysing at least a galactolipid and/or capable of transferring an acyl group from at least a galactolipid to one or more acyl acceptor substrates, wherein the enzyme comprises an amino acid sequence as shown in SEQ ID No. 4 or an amino acid sequence which has at least 60% identity thereto.
- the present invention provides a nucleic acid encoding a lipolytic enzyme comprising an amino acid sequence as shown in SEQ ID No. 4 or an amino acid sequence which has at least 60% identity therewith.
- SEQ ID No. 3 is shown in Figure 3 and SEQ ID No.4 is shown in Figure 4.
- the present invention yet further provides a nucleic acid encoding a lipolytic enzyme, which nucleic acid is selected from the group consisting of: a) a nucleic acid comprising a nucleotide sequence shown in SEQ ID No. 3; b) a nucleic acid which is related to the nucleotide sequence of SEQ ID No. 3 by the degeneration of the genetic code; and c) a nucleic acid comprising a nucleotide sequence which has at least 70% identity with the nucleotide sequence shown in SEQ ID No. 3.
- the present invention yet further provides the use of a lipolytic enzyme according to the present invention in a substrate (preferably a foodstuff) for preparing a lyso- glycolipid, for example digalactosyl monoglyceride (DGMG) or monogalactosyl monoglyceride (MGMG) by treatment of a glycolipid (e.g. digalactosyl diglyceride (DGDG) or monogalactosyl diglyceride (MGDG)) with the lipolytic enzyme according to the present invention to produce the partial hydrolysis product, i.e. the lyso- glycolipid.
- DGMG digalactosyl monoglyceride
- MGDG monogalactosyl diglyceride
- the present invention provides the use of a lipolytic enzyme according to the present invention in a substrate (preferably a foodstuff) for preparing a lyso-phospholipid, for example lysolecithin, by treatment of a phospholipid (e.g. lecithin) with the enzyme according to the present invention to produce a partial hydrolysis product, i.e. a lyso-phospholipid.
- a substrate preferably a foodstuff
- a lyso-phospholipid for example lysolecithin
- a phospholipid e.g. lecithin
- the present invention relates to a method of preparing a foodstuff the method comprising admixing a lipolytic enzyme of the present invention with one or more ingredients of the foodstuff.
- Another broad aspect of the present invention relates to a method of preparing a baked product from a dough, the method comprising admixing a lipolytic enzyme of the present invention with the dough.
- the present invention relates to a method of preparing a dairy product, the method comprising admixing a lipolytic enzyme of the present invention with one or more ingredients of the dairy product.
- the present invention relates to the use of a lipolytic enzyme of the present invention in the manufacture of a dairy product to reduce one or more of the following detrimental effects: off-odours and/or off-flavours and/or soapy taste.
- a lipolytic enzyme according to the present invention in a process of treating egg or egg-based products to produce lysophospholipids.
- a lipolytic enzyme according to the present invention in a process of treating egg or egg-based products to produce lysoglycolipids.
- a further aspect of the present invention provides a process of enzymatic degumming of vegetable or edible oils, comprising treating the edible or vegetable oil with a lipolytic enzyme according to the present invention so as to hydrolyse a major part of the polar lipids (e.g. phospholipid and/or glycolipid).
- a lipolytic enzyme according to the present invention so as to hydrolyse a major part of the polar lipids (e.g. phospholipid and/or glycolipid).
- the present invention provides the use of a lipolytic enzyme according to the present invention in a process comprising treatment of a phospholipid so as to hydrolyse fatty acyl groups.
- the present invention provides the use of a lipolytic enzyme according to the present invention in a process for reducing the content of a phospholipid in an edible oil, comprising treating the oil with the lipolytic enzyme according to the present invention so as to hydrolyse a major part of the phospholipid, and separating an aqueous phase containing the hydrolysed phospholipid from the oil.
- a method of preparing a lipolytic enzyme comprising transforming a host cell with a recombinant nucleic acid comprising a nucleotide sequence coding for the lipolytic enzyme, the host cell being capable of expressing the nucleotide sequence coding for the polypeptide of the lipolytic enzyme, cultivating the transformed host cell under conditions where the nucleic acid is expressed and harvesting the lipolytic enzyme.
- the present invention relates to the use of a lipolytic enzyme in accordance with the present invention in the bioconversion of polar lipids (preferably glycolipids) to make high value products, such as carbohydrate esters and/or protein esters and/or protein subunit esters and/or a hydroxy acid ester.
- polar lipids preferably glycolipids
- Another aspect of the present invention relates to the use of a lipolytic enzyme in accordance with the present invention in a process of enzymatic degumming of vegetable or edible oil, comprising treating said edible or vegetable oil with said lipolytic enzyme so as to hydrolyse a major part of the polar lipids.
- a further aspect of the present invention relates to the use of a lipolytic enzyme in accordance with the present invention in a process comprising treatment of a phospholipid so as to hydrolyse fatty acyl groups.
- the present invention yet further relates to an immobilised lipolytic enzyme in accordance with the present invention.
- Another aspect of the present invention relates to a method of preparing a lysoglycolipid comprising treating a substrate comprising a glycolipid with at least one lipolytic enzyme to produce said lysoglycolipid, wherein said lipolytic enzyme has glycolipase activity and wherein said lipolytic enzyme is obtainable from one of the following genera: Streptomyces, Corynebacterium and Thermobifida.
- a further aspect of the present invention relates to a method of preparing a lysophospholipid comprising treating a substrate comprising a phospholipid with at least one lipolytic enzyme to produce said lysophospholipid, wherein said lipolytic enzyme has phospholipase activity and wherein said lipolytic enzyme is obtainable from one of the following genera: Streptomyces, Corynebacterium and Thermobifida.
- Another aspect of the present invention relates to a method of enzymatic degumming of vegetable or edible oil, comprising treating said edible or vegetable oil with a lipolytic enzyme obtainable from one of the following genera: Streptomyces, Corynebacterium and Thermobifida capable of hydrolysing a major part of me polar lipids.
- the present invention further relates to a method of bioconversion of polar lipids to make high value products comprising treating said polar lipids with a lipolytic enzyme obtainable from one of the following genera: Streptomyces, Corynebacterium and Thermobifida to produce said high value products, wherein said lipolytic enzyme is capable of hydrolysing said polar lipids.
- a lipolytic enzyme obtainable from one of the following genera: Streptomyces, Corynebacterium and Thermobifida to produce said high value products, wherein said lipolytic enzyme is capable of hydrolysing said polar lipids.
- Another aspect of the present invention relates to a method of preparing a foodstuff comprising admixing at least one lipolytic enzyme with one or more ingredients of a foodstuff wherein said lipolytic enzyme is capable of hydrolysing a glycolipid and/or a phospholipid present in or as at least one of said ingredients and wherein said lipolytic enzyme is obtainable from one of the following genera: Streptomyces, Corynebacterium and Thermobifida.
- a further aspect of the present invention relates the use of a lipolytic enzyme in a substrate for preparing a lysophospholipid wherein said lipolytic enzyme has phospholipase activity and wherein said lipolytic enzyme is obtainable from one of the following: Streptomyces, Corynebacterium and Thermobifida.
- the present invention additionally relates to the use of a lipolytic enzyme obtainable from one of the following genera: Streptomyces, Corynebacterium and Thermobifida for enzymatic degumming of vegetable or edible oil so as to hydrolyse a major part of the polar lipids.
- a lipolytic enzyme obtainable from one of the following genera: Streptomyces, Corynebacterium and Thermobifida in a process comprising treatment of a phospholipid so as to hydrolyse fatty acyl groups.
- a further aspect of the present invention relates to use of a lipolytic enzyme in the bioconversion of polar lipids to make high value products, wherein said lipolytic enzyme is capable of hydrolysing said polar lipids and wherein said lipolytic enzymes is obtainable from one of the following genera: Streptomyces, Corynebacterium and Thermobifida.
- a further aspect of the present invention relates to the use of a lipolytic enzyme obtainable from one of the following genera: Streptomyces, Corynebacterium and Thermobifida in the preparation of a foodstuff, wherein said lipolytic enzyme is capable of hydrolysing a glycolipid and/or a phospholipid.
- the present invention also encompasses methods of expressing the nucleotide sequence for use in the present invention using the same, such as expression in a host cell; including methods for transferring same.
- the present invention further encompasses methods of isolating the nucleotide sequence, such as isolating from a host cell.
- amino acid sequence for use in the present invention includes: a construct encoding the amino acid sequences for use in the present invention; a vector encoding the amino acid sequences for use in the present invention; a plasmid encoding the amino acid sequences for use in the present invention; a transformed cell expressing the amino acid sequences for use in the present invention; a transformed tissue expressing the amino acid sequences for use in the present invention; a transformed organ expressing the amino acid sequences for use in the present invention; a transformed host expressing the amino acid sequences for use in the present invention; a transformed organism expressing the amino acid sequences for use in the present invention.
- the present invention also encompasses methods of purifying the amino acid sequence for use in the present invention using the same, such as expression in a host cell; including methods of transferring same, and then purifying said sequence.
- the lipolytic enzyme for use in the methods and uses according to the present invention may be a lipolytic enzyme comprising any one of the amino acid sequences shown as SEQ ID No. 4, 5, 7, 8, 12, 14 or 16 or an amino acid sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97% or 98% identity therewith, or encoded by any one of the nucleotide sequences shown as SEQ ID No. 3, 6, 9, 13, 15 or 17 or a nucleotide sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97% or 98% identity therewith.
- the lipolytic enzyme for use in the methods and uses according to the present invention is a lipolytic enzyme capable of hydrolysing at least galactolipids and/or capable of transferring an acyl group from at least a galactolipid to one or more acyl acceptor substrates, wherein the enzyme is obtainable, preferably obtained, from Streptomyces species.
- the lipolytic enzyme for use in the methods and uses according to the present invention is preferably a lipolytic enzyme capable of hydrolysing at least galactolipids and/or capable of transferring an acyl group from at least a galactolipid to one or more acyl acceptor substrates, wherein the enzyme is encoded by a nucleic acid selected from the group consisting of: a) a nucleic acid comprising a nucleotide sequence shown in SEQ ID No. 3; b) a nucleic acid which is related to the nucleotide sequence of SEQ DD No. 3 by the degeneration of the genetic code; and c) a nucleic acid comprising a nucleotide sequence which has at least 70% identity with the nucleotide sequence shown in SEQ ID No. 3.
- a nucleic acid selected from the group consisting of: a) a nucleic acid comprising a nucleotide sequence shown in SEQ ID No. 3; b) a nucleic acid
- the lipolytic enzyme for use in the methods and uses according to the present invention is preferably a lipolytic enzyme comprising an amino acid sequence as shown in SEQ ID No. 4 or an amino acid sequence which has at least 60% identity thereto.
- the lipolytic enzyme for use in the methods and uses according to the present invention is preferably a lipolytic enzyme capable of hydrolysing at least a galactolipid and/or capable of transferring an acyl group from at least a galactolipid to one or more acyl acceptor substrates, wherein the enzyme comprises an amino acid sequence as shown in SEQ ID No.4 or an amino acid sequence which has at least 60% identity thereto.
- the lipolytic enzyme for use in the methods and uses according to the present invention is a lipolytic enzyme capable of hydrolysing at least galactolipids and/or capable of transferring an acyl group from at least a galactolipid to one or more acyl acceptor substrates, wherein the enzyme is obtainable, preferably obtained, from Thermobifida species, preferably Thermobifidafusca.
- the lipolytic enzyme for use in the methods and uses according to the present invention is a lipolytic enzyme capable of hydrolysing at least galactolipids and/or capable of transferring an acyl group from at least a galactolipid to one or more acyl acceptor substrates, wherein the enzyme is obtainable, preferably obtained, from Corynebacterium species, preferably Corynebacterium efficiens.
- the lipolytic enzyme for use in the methods and uses according to the present invention may be a lipolytic enzyme comprising any one of the amino acid sequences shown as SEQ ID No. 4, 5, 7, 8, 12, 14 or 16 or an amino acid sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97% or 98% identity therewith, or encoded by any one of the nucleotide sequences shown as SEQ ID No. 3, 6, 9, 13, 15 or 17 or a nucleotide sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97% or 98% identity therewith.
- the lipolytic enzyme for use in the methods and uses according to the present invention may be a lipolytic enzyme comprising any one of amino sequences shown as SEQ ID No. 5, 7, 8, 14 or 16 or an amino acid sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97% or 98% identity therewith for the uses described herein.
- the lipolytic enzyme for use in the methods and uses according to the present invention may be a lipolytic enzyme comprising any one of amino sequences shown as SEQ ID No. 5, 7 or 16 or an amino acid sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97% or 98% identity therewith for the uses described herein.
- the lipolytic enzyme for use in the methods and uses according to the present invention may be a lipolytic enzyme comprising the amino acid sequence shown as SEQ ID No. 16 or an amino acid sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97% or 98% identity therewith.
- the lipolytic enzyme for use in the methods and uses according to the present invention may be a lipolytic enzyme comprising the amino acid sequence shown as SEQ ID No.s 12 or 14 or an amino acid sequence which has at least 80%, 85%, 90%, 95%, 96%, 97% or 98% identity therewith.
- the lipolytic enzyme for use in the methods and uses according to the present invention may be a lipolytic enzyme comprising the amino acid sequence shown as SEQ ID No. 8 or an amino acid sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97% or 98% identity therewith.
- the lipolytic enzyme for use in the methods and uses according to the present invention may be a lipolytic enzyme capable of hydrolysing at least galactolipids and/or capable of transferring an acyl group from at least a galactolipid to one or more acyl acceptor substrates, wherein the enzyme is encoded by a nucleic acid selected from the group consisting of: a) a nucleic acid comprising a nucleotide sequence shown in SEQ BD No. 3; b) a nucleic acid which is related to the nucleotide sequence of SEQ ID No. 3 by the degeneration of the genetic code; and c) a nucleic acid comprising a nucleotide sequence which has at least 70% identity with the nucleotide sequence shown in SEQ ID No. 3.
- a nucleic acid selected from the group consisting of: a) a nucleic acid comprising a nucleotide sequence shown in SEQ BD No. 3; b) a nucleic acid
- the lipolytic enzyme according to the present invention may be a lipolytic enzyme obtainable, preferably obtained, from the Streptomyces strains L130 or Ll 31 deposited by Danisco A/S of Langebrogade 1, DK-1001 Copenhagen K 5 Denmark under the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the purposes of Patent Procedure at the National Collection of Industrial, Marine and Food Bacteria (NCIMB) 23 St. Machar Street, Aberdeen Scotland, GB on 25 June 2004 under accession numbers NCIMB 41226 and NCIMB 41227, respectively.
- the lipolytic enzyme according to the present invention acts on at least a glycolipid, such as digalactosyldiglyceride (DGDG) for example.
- DGDG digalactosyldiglyceride
- the lipolytic enzyme according to the present invention may also act on one or more other polar lipid substrates, such as a phospholipid, for example a lecithin, e.g. phosphatidy
- the lipolytic enzyme according to the present invention hydrolyses a glycolipid, such as digalactosyldiglyceride (DGDG) for example, and also a phospholipid, such as a lecithin, e.g. phosphatidylcholine.
- DGDG digalactosyldiglyceride
- phospholipid such as a lecithin, e.g. phosphatidylcholine.
- the lipolytic enzyme according to the present invention acts on glycolipids such as DGDG or MGDG.
- the lipolytic enzyme according to the present invention hydrolyses DGDG to DGMG and/or MGDG to MGMG.
- the lipolytic enzyme according to the present invention hydrolyses lecithin to lysolecithin.
- the lipolytic enzyme is capable of transferring an acyl group from at least a glycolipid to a donor substrate
- the polar lipid substrate may be referred to herein as the "lipid acyl donor”.
- the enzyme according to the present invention which as well as having phospholipase and/or glycolipase activity (generally classified as E.C. 3.1.1.26;
- acyltransferase activity (generally classified as E.C. 2.3.1.x), whereby the enzyme is capable of transferring an acyl group from a lipid acyl donor to one or more acceptor substrates, such as one or more of the following: a sterol; a stanol; a carbohydrate; a protein; a protein subunit; glycerol.
- the lipolytic enzyme for use in the methods and/or uses of the present invention may be capable of transferring an acyl group from a polar lipid (as defined herein) to one or more of the following acyl acceptor substrates: a sterol, a stanol, a carbohydrate, a protein or subunits thereof, or a glycerol.
- acyl acceptor may be any compound comprising a hydroxy group (-OH), such as for example, polyvalent alcohols, including glycerol; sterol; stanols; carbohydrates; hydroxy acids including fruit acids, citric acid, tartaric acid, lactic acid and ascorbic acid; proteins or a sub-unit thereof, such as amino acids, protein hydrolysates and peptides (partly hydrolysed protein) for example; and mixtures and derivatives thereof.
- a hydroxy group such as for example, polyvalent alcohols, including glycerol; sterol; stanols; carbohydrates; hydroxy acids including fruit acids, citric acid, tartaric acid, lactic acid and ascorbic acid; proteins or a sub-unit thereof, such as amino acids, protein hydrolysates and peptides (partly hydrolysed protein) for example; and mixtures and derivatives thereof.
- the "acyl acceptor" according to the present invention may be preferably not water.
- the acyl acceptor is preferably not a monoglyceride and/or a diglyceride.
- the enzyme is capable of transferring an acyl group from a lipid to a sterol and/or a stanol. In one aspect, preferably the enzyme is capable of transferring an acyl group from a lipid to a carbohydrate.
- the enzyme is capable of transferring an acyl group from a lipid to a protein or a subunit thereof.
- the protein subunit may be one or more of the following: an amino acid, a protein hydrolysate, a peptide, a dipeptide, an oligopeptide, a polypeptide.
- the acyl acceptor may be one or more of the following constituents of the protein or protein subunit: a serine, a threonine, a tyrosine, or a cysteine.
- the amino acid may be any suitable amino acid.
- the amino acid may be one or more of a serine, a threonine, a tyrosine, or a cysteine for example.
- the enzyme is capable of transferring an acyl group from a lipid to glycerol.
- the enzyme is capable of transferring an acyl group from a lipid to a hydroxy acid.
- the enzyme is capable of transferring an acyl group from a lipid to a polyvalent alcohol.
- the lipolytic enzyme may, as well as being able to transfer an acyl group from a lipid to a sterol and/or a stanol, additionally be able to transfer the acyl group from a lipid to one or more of the following: a carbohydrate, a protein, a protein subunit, glycerol.
- lecithin as used herein encompasses phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, phosphatidylserine and phosphatidylglycerol.
- the lipid substrate is at least a glycolipid, such as DGDG for example.
- the lipid substrate may be additionally a phospholipid, such as lecithin, for example phosphatidylcholine.
- phospholipid substrates in accordance with the present invention may be one or more of N acyl phosphatidyl ethanolamine (APE) or N acyl lyso-phosphatidyl ethanolamine (ALPE).
- the lipid substrate is a food lipid, that is to say a lipid component of a foodstuff.
- the lipolytic enzyme according to the present invention is incapable, or substantially incapable, of acting on a triglyceride and/or a 1- monoglyceride and/or 2-monoglyceride.
- the lipolytic enzyme according to the present invention has no activity or no significant activity on triglyceride and/or 1-monoglycerides and/or 2- monoglycerides.
- the lipid substrate or lipid acyl donor may be one or more lipids present in one or more of the following substrates: fats, including lard, tallow and butter fat; oils including oils extracted from or derived from palm oil, sunflower oil, soya bean oil, safflower oil, cotton seed oil, ground nut oil, corn oil, olive oil, peanut oil, coconut oil, and rapeseed oil.
- Lecithin from soya, rapeseed or egg yolk is also a suitable lipid substrate.
- the lipid substrate may be an oat lipid or other plant based material containing galactolipids.
- the lipid substrate or lipid acyl donor is preferably lecithin (such as phosphatidylcholine) in egg yolk.
- the lipid may be selected from lipids having a fatty acid chain length of from 8 to 22 carbons.
- the lipid may be selected from lipids having a fatty acid chain length of from 16 to 22 carbons, more preferably of from 16 to 20 carbons.
- the lipid may be selected from lipids having a fatty acid chain length of no greater than 14 carbons, suitably from lipids having a fatty acid chain length of from 4 to 14 carbons, suitably 4 to 10 carbons, suitably 4 to 8 carbons.
- the lipolytic enzyme according to the present invention exhibits at least glycolipase activity (E.C. 3.1.1.26).
- the lipolytic enzyme according to the present invention may also exhibit phospholipase A2 activity (E.C. 3.1.1.4) and/or phospholipase Al activity (E.C. 3.1.1.32).
- the lipolytic enzyme according to the present invention may solely have glycolipase activity (E.C. 3.1.1.26).
- the lipolytic enzyme according to the present invention is a galactolipase (E.C. 3.1.1.26).
- the fact that the enzyme is designated at a galactolipase does not, however, prevent it from having other side-activities, such as activity towards other polar lipids for example.
- the lipolytic enzyme according to the present invention may be capable of transferring an acyl group from a glyco ⁇ ipid and/or a phospholipid to one or more acceptor substrates.
- the acceptor substrate may be one or more of the following substrates: a sterol, a stanol, a carbohydrate, a protein, glycerol.
- polar lipids as used herein means phospholipids and/or glycolipids. In some aspects, the term polar lipids preferably means at least glycolipids.
- glycolipase activity phospholipase activity
- triacylglycerol lipase activity of an enzyme can be determined using the assays presented hereinbelow.
- Assay procedure 400 ⁇ L substrate was added to an 1.5 mL Eppendorf tube and placed in an Eppendorf
- Enzyme activity GLU at pH 7 was calculated as micromole fatty acid produced per minute under assay conditions
- Assay procedure 400 ⁇ L substrate was added to a 1.5 mL Eppendorf tube and placed in an Eppendorf
- Enzyme activity PLU-7 at pH 7 was calculated as micromole fatty acid produced per minute under assay conditions
- 1 LIPU is defined as the quantity of enzyme which can liberate 1 micromole butyric acid per min. under assay conditions.
- the lipolytic enzyme according to the present invention is a wild-type lipolytic enzyme.
- Natural and wild type as used herein mean a naturally-occurring enzyme. That is to say an enzyme expressed from the endogenous genetic code and isolated from its endogenous host organism and/or a heterologously produced enzyme which has not been mutated (i.e. does not contain amino acid deletions, additions or substitutions) ' when compared with the mature protein sequence (after co- and post- translational cleavage events) endogenously produced.
- Natural and wild-type proteins of the present invention may be encoded by codon optimised polynucleotides for heterologous expression, and may also comprise a non-endogenous signal peptide selected for expression in that host.
- variant means a protein expressed from a non-endogenous genetic code resulting in one or more amino acid alterations (i.e. amino acid deletions, additions or substitutions) when compared with the natural or wild-type sequence within the mature protein sequence.
- the lipolytic enzyme according to the present invention is obtainable (suitably may be obtained) from a bacterium.
- the lipolytic enzyme according to the present invention may be obtainable (preferably obtained) from Streptomyces spp.
- the lipolytic enzyme according to the present invention may be obtainable (preferably obtained) from Streptomyces strain L131 or Streptomyces strain L130.
- the lipolytic enzyme according to the present invention comprises an amino acid sequence which has at least 70%, preferably at least 75%, preferably at least 80%, preferably at least 90%, preferably at least 95%, preferably at least 98%, preferably at least 99% identity with the amino acid sequence shown as SEQ ID No. 4.
- the nucleic acid encoding the lipolytic enzyme according to the present invention comprises a nucleotide sequence which has at least 75%, preferably at least 80%, preferably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 98%, preferably at least 99% identity with the nucleotide sequence shown in SEQ ID No. 3.
- the pH optimum of the enzyme on a galactolipid substrate is about 6-8, preferably about 6.5 to 7.5, more preferably about 7.
- the lipolytic enzyme according to the present invention may not be inhibited or not significantly be inhibited by lipases inhibitors present in wheat flour.
- the term "not significantly inhibited” as used herein means that the enzyme is less sensitive to lipase inhibitors present in the wheat flour when compared to an equivalent dosage (PLU) of LipopanFTM (Novozymes A/S, Denmark), as based on the standard phospholipase (PLU-T) assay defined herein.
- the lipolytic enzyme according to the present invention is capable of hydrolysing at least 10% of the galactolipid diester in the substrate (i.e. in the foodstuff, e.g. dough, for instance) to the monoester.
- the enzyme is capable of hydrolysing at least 20%, more preferably at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80% or at least 90% of the galactolipid diester to the monoester.
- the galactolipid diester may be one or more of MGDG or DGDG and the monoester may be one or more of MGMG or DGMG, respectively.
- the lipolytic enzyme according to the present invention may be isolated from a fermentation broth of Streptomyces strain L131 or Streptomyces strain L130.
- the enzyme may be purified by liquid chromatography.
- the amino acid sequence of the purified lipolytic enzyme may be determined by Edman degradation, LC-MS and MALDI-TOF analysis.
- the enzyme as defined herein may catalyse one or more of the following reactions: interesterification, transesterification, alcoholysis, hydrolysis.
- interesterification refers to the enzymatic catalysed transfer of acyl groups between a lipid donor and lipid acceptor, wherein the lipid donor is not a free acyl group.
- transesterification as used herein means the enzymatic catalysed transfer of an acyl group from a lipid donor (other than a free fatty acid) to an acyl acceptor (other than water).
- alcoholysis refers to the enzymatic cleavage of a covalent bond of an acid derivative by reaction with an alcohol ROH so that one of the products combines with the H of the alcohol and the other product combines with the OR group of the alcohol.
- alcohol refers to an alkyl compound containing a hydroxyl group.
- hydrolysis refers to the enzymatic catalysed transfer of an acyl group from a lipid to the OH group of a water molecule. Acyl transfer which results from hydrolysis requires the separation of the water molecule.
- foodstuff' as used herein means a substance which is suitable for human and/or animal consumption.
- the term "foodstuff' as used herein may mean a foodstuff in a form which is ready for consumption.
- foodstuff as used herein may mean one or more food materials which are used in the preparation of a foodstuff.
- foodstuff encompasses both baked goods produced from dough as well as the dough used in the preparation of said baked goods.
- the present invention provides a foodstuff as defined above wherein the foodstuff is selected from one or more of the following: eggs, egg-based products, including but not limited to mayonnaise, salad dressings, sauces, ice creams, egg powder, modified egg yolk and products made therefrom; baked goods, including breads, cakes, sweet dough products, laminated doughs, liquid batters, muffins, doughnuts, biscuits, crackers and cookies; confectionery, including chocolate, candies, caramels, halawa, gums, including sugar free and sugar sweetened gums, bubble gum, soft bubble gum, chewing gum and puddings; frozen products including sorbets, preferably frozen dairy products, including ice cream and ice milk; dairy products, including cheese, butter, milk, coffee cream, whipped cream, custard cream, milk drinks and yoghurts; mousses, whipped vegetable creams, meat products, including processed meat products; edible oils and fats, aerated and non-aerated whipped products, oil-in-water emulsions
- the foodstuff in accordance with the present invention may be a "fine foods", including cakes, pastry, confectionery, chocolates, fudge and the like.
- the foodstuff in accordance with the present invention may be a dough product or a baked product, such as a bread, a fried product, a snack, cakes, pies, brownies, cookies, noodles, snack items such as crackers, graham crackers, pretzels, and potato chips, and pasta.
- the foodstuff in accordance with the present invention may be a plant derived food product such as flours, pre-mixes, oils, fats, cocoa butter, coffee whitener, salad dressings, margarine, spreads, peanut butter, shortenings, ice cream, cooking oils.
- a plant derived food product such as flours, pre-mixes, oils, fats, cocoa butter, coffee whitener, salad dressings, margarine, spreads, peanut butter, shortenings, ice cream, cooking oils.
- the foodstuff in accordance with the present invention may be a dairy product, including butter, milk, cream, cheese such as natural, processed, and imitation cheeses in a variety of forms (including shredded, block, slices or grated), cream cheese, ice cream, frozen desserts, yoghurt, yoghurt drinks, butter fat, anhydrous milk fat, other dairy products.
- the enzyme according to the present invention may improve fat stability in dairy products.
- a lipolytic enzyme in accordance with the present invention can advantageously be used to produce cheese.
- the lipolytic enzyme catalyses the hydrolysis of phospholipids in the milk which contributes to increased cheese yield.
- the lipolytic enzyme according to the present invention may be added to milk (referred to as cheese milk) prior to or during the cheese making process.
- the foodstuff in accordance with the present invention may be a food product containing animal derived ingredients, such as processed meat products, cooking oils, shortenings.
- the foodstuff in accordance with the present invention may be a beverage, a fruit, mixed fruit, a vegetable or wine.
- the beverage may contain up to 20 g/1 of added phytosterols.
- the foodstuff in accordance with the present invention may be an animal feed.
- the animal feed may be enriched with phytosterol and/or phytostanols, preferably with beta-sitosterol/stanol.
- the animal feed may be a poultry feed.
- the present invention may be used to lower the cholesterol content of eggs produced by poultry fed on the foodstuff according to the present invention.
- the foodstuff is selected from one or more of the following: eggs, egg-based products, including mayonnaise, salad dressings, sauces, ice cream, egg powder, modified egg yolk and products made therefrom.
- the foodstuff according to the present invention is a water containing foodstuff.
- the foodstuff may be comprised of 10-98% water, suitably 14- 98%, suitably of 18-98% water, suitably of 20-98%, suitably of 40-98%, suitably of 50-98%, suitably of 70-98%, suitably of 75-98%.
- the foodstuff in accordance with the present invention may not be a pure plant derived oil, such as olive oil, sunflower oil, peanut oil, rapeseed oil for instance.
- the foodstuff according to the present invention may comprise an oil, but the foodstuff is not primarily composed of oil or mixtures of oil.
- the foodstuff comprises less than 95% lipids, preferably less than 90% lipids, preferably less than 85%, preferably less than 80% lipids.
- oil may be a component of the foodstuff, but preferably the foodstuff is not an o ⁇ per se.
- free fatty acids can be detrimental to foodstuffs.
- Free fatty acids have been linked with off-odours and/or off-flavours in foodstuffs, as well other detrimental effects, including a soapy taste in dairy products such as cheese for instance.
- the lipolytic enzyme is capable of transferring the fatty acid from the lipid to an acyl acceptor, for example a sterol and/or a stanol.
- an acyl acceptor for example a sterol and/or a stanol.
- a lipolytic enzyme capable of transferring an acyl group according to the present invention may provide one or more of the following unexpected technical effects in the production of cheese: a decrease in the oiling-off effect in cheese; an increase in cheese yield; an improvement in flavour; a reduced mal-odour; a reduced "soapy" taste.
- a lipolytic enzyme taught herein which can transfer the acyl group to a carbohydrate as well as to a sterol and/or a stanol is particularly advantageous for foodstuffs comprising eggs.
- the presence of sugars, in particular glucose, in eggs and egg products is often seen as disadvantageous.
- Egg yolk may comprise up to 1% glucose. In accordance with the present invention this unwanted sugar can be readily removed by "esterifying" the sugar to form a sugar ester.
- a lipolytic enzyme taught herein is capable of transferring the fatty acid from the lipid to an acyl acceptor which reduces the level of diglycerides in the oil without increasing or significantly increasing the level of free fatty acids.
- a lipolytic enzyme taught herein is able to hydrolyse a major part of the phospholipids in an edible or vegetable oil. This is highly advantageous in the enzymatic degumming of vegetable or edible oils.
- the lipolytic enzyme may be capable of transferring the fatty acid from the lipid to an acyl acceptor.
- the overall level of free fatty acids in the oil does not increase or increases only to an insignificant degree.
- the production of free fatty acids can be detrimental in the edible oil.
- the method according to the present invention results in the degumming of an edible oil wherein the accumulation of free fatty acids is reduced and/or eliminated.
- the lipolytic enzyme according to the present invention may be used with one or more conventional emulsifiers, including for example monoglycerides, diacetyl tartaric acid esters of mono- and diglycerides of fatty acids, sugar esters, sodium stearoyl lactylate (SSL) and lecithins.
- conventional emulsifiers including for example monoglycerides, diacetyl tartaric acid esters of mono- and diglycerides of fatty acids, sugar esters, sodium stearoyl lactylate (SSL) and lecithins.
- the enzyme according to the present invention may be used with one or more other suitable food grade enzymes.
- at least one further enzyme may be added to the baked product and/or the dough.
- Such further enzymes include starch degrading enzymes such as endo- or exoamylases, pullulanases, debranching enzymes, hemicellulases including xylanases, cellulases, oxidoreductases, e.g.
- glucose oxidase pyranose oxidase, sulfhydryl oxidase or a carbohydrate oxidase such as one which oxidises maltose, for example hexose oxidase (HOX), lipases, phospholipases and hexose oxidase, proteases, and acyltransferases (such as those described in PCT/IB2004/000575 for instance).
- HOX hexose oxidase
- lipases phospholipases and hexose oxidase
- proteases and acyltransferases
- the present invention encompasses food enzyme compositions, including bread and/or dough improving compositions comprising the enzyme according to the present invention, and optionally further comprising another enzyme, such as one or more other suitable food grade enzymes, including starch degrading enzymes such as endo- or exoamylases, pullulanases, debranching enzymes, hemicellulases including xylanases, cellulases, oxidoreductases, e.g.
- glucose oxidase pyranose oxidase, sulfhydryl oxidase or a carbohydrate oxidase such as one which oxidises maltose, for example hexose oxidase (HOX), lipases, phospholipases and hexose oxidase, proteases and acyltransferases (such as those described in PCT/EB2004/000575 for instance).
- HOX hexose oxidase
- lipases phospholipases and hexose oxidase
- proteases acyltransferases
- the lipolytic enzyme according to the present invention may be added in combination or sequentially with one or more enzyme substrates.
- the lipolytic enzyme according to the present invention may be added together with one or more polar lipid substrates and/or one or more acyl acceptor substrates.
- the lipolytic enzyme according to the present invention may be used with one or more hydroxy acids, including for example tartaric acid, citric acid, lactic acid, succinic acid or ascorbic acid for example.
- improved properties means any property which may be improved by the action of the lipolytic enzyme of the present invention, hi particular, the use of the lipolytic enzyme according to the present invention results in one or more of the following characteristics: increased volume of the baked product; improved crumb structure of the baked product; anti-staling properties in the baked product; increased strength, increased stability, reduced stickiness and/or improved machinability of the dough.
- the improved properties are evaluated by comparison with a dough and/or a baked product prepared without addition of the lipolytic enzyme according to the present invention.
- baked product includes a product prepared from a dough.
- baked products include one or more of the following: bread (including white, whole-meal and rye bread), typically in the form of loaves or rolls, steam buns, French baguette-type bread, pita bread, tacos, corn tortilla, wheat tortilla, cakes, pancakes, biscuits, crisp bread, pasta, noodles and the like.
- the dough in accordance with the present invention may be a leavened dough or a dough to be subjected to leavening.
- the dough may be leavened in various ways such as by adding sodium bicarbonate or the like, or by adding a suitable yeast culture such as a culture of Saccharomyces cerevisiae (baker's yeast).
- the present invention further relates to the use of the lipolytic enzyme in accordance with the present invention to produce a pasta dough, preferably prepared from durum flour or a flour of comparable quality.
- the lipolytic enzyme according to the present invention is suitable for use in the enzymatic degumming of vegetable or edible oils.
- the edible or vegetable oil is treated with lipolytic enzyme according to the present invention so as to hydrolyse a major part of the polar lipids (e.g. phospholipid).
- the fatty acyl groups are hydrolysed from the polar lipids.
- the degumming process typically results in the reduction of the content of the polar lipids, particularly of phospholipids, in an edible oil due to hydrolyse of a major part (i.e. more than 50%) of the polar lipid, e.g. phospholipid.
- the aqueous phase containing the hydrolysed polar lipid e.g. phospholipid
- the edible or vegetable oil may initially (pre-treatment with the enzyme according to the present invention) have a phosphorus content of 50-250 ppm.
- the present invention relates to the use of the lipolytic enzyme in accordance with the present invention in the bioconversion of polar lipids (preferably glycolipids) to make high value products, such as carbohydrate esters and/or protein esters and/or protein subunit esters and/or a hydroxy acid ester.
- a lipolytic enzyme particularly a lipolytic enzyme capable of transferring acyl groups from a polar lipid substrate (preferably a glycolipid) to a acyl acceptor, in the bioconversion of polar lipids and the advantages thereof is detailed in PCT/EB2004/004374 incorporated herein by reference.
- the lipolytic enzyme for use in the methods of the present invention may be immobilised.
- the admixture comprising an acyl donor, optionally an acyl acceptor, and optionally water may be passed through a column for example comprising the immobilised enzyme.
- the immobilised enzyme may be used in a flow reactor or in a batch reactor containing a reaction mixture which comprises a lipid acyl donor and optionally an acyl acceptor dissolved in water.
- a reaction mixture which comprises a lipid acyl donor and optionally an acyl acceptor dissolved in water.
- the reaction mixture may be optionally stirred or sonicated.
- the reaction product may be fractionated for example by hydrophobic interaction chromatography, crystallisation or high vacuum distillation.
- Immobilised lipid acyl transferase can be prepared using immobilisation techniques known in the art. There are numerous methods of preparing immobilised enzymes, which will be apparent to a person skilled in the art (for example the techniques referred to in EP 0 746 608; or Balcao V.M. et al Enzyme Microb Technol. 1996 May 1; 18(6):392-416; or Retz et al Chem Phys Lipids 1998 June:93(l-2) : 3-14; Bornscheuer et al Trends Biotechnol. 2002 Oct; 20(10):433-7; Plou et al Biotechnology 92 (2002) 55-66; Warmuth et al 1992 Bio Forum 9, 282-283; Ferrer et al 2000 J.
- Techniques which may be used herein include covalent coupling to Eupergit C, adsorption on polypropylene and silica-granulation for example.
- the lipolytic enzyme for use in accordance with the present invention and/or the methods described herein is preferably a lipolytic enzyme capable of hydrolysing at least galactolipids and/or capable of transferring an acyl group from at least a galactolipid to one or more acyl acceptor substrates, wherein the enzyme is encoded by a nucleic acid selected from the group consisting of: d) a nucleic acid comprising a nucleotide sequence shown in SEQ ID No. 3; e) a nucleic acid which is related to the nucleotide sequence of SEQ ID No. 3 by the degeneration of the genetic code; and f) a nucleic acid comprising a nucleotide sequence which has at least 70% identity with the nucleotide sequence shown in SEQ ID No. 3.
- the lipolytic enzyme used in accordance with the present invention and/or in the methods described herein is a lipolytic enzyme comprising an amino acid sequence as shown in SEQ ID No. 4 or an amino acid sequence which has at least 60% identity thereto.
- the lipolytic enzyme for use in accordance with the present invention and/or in the methods of the present invention may be any lipolytic enzyme obtainable from Streptomyces species which is capable of hydrolysing at least a galactolipid and/or capable of transferring an acyl group from a galactolipid to one or more acyl acceptor substrates.
- Suitable lipolytic enzymes having galactolipase activity for use in accordance with the present invention and/or in the methods of the present invention may comprise any one of the following amino acid sequences and/or be encoded by the following nucleotide sequences:
- the present invention provides the use of a lipolytic enzyme comprising any one of the amino acid sequences shown as SEQ ID No. 4, 5, 7, 8, 12, 14, or 16 or an amino acid sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97% or 98% identity therewith, or encoded by any one of the nucleotide sequences shown as SEQ ID No.
- a nucleotide sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97% or 98% identity therewith, in a foodstuff for the preparation of a lyso-glycolipid, for example digalactosyl monoglyceride (DGMG) or monogalactosyl monoglyceride (MGMG) by treatment of a glycolipid (e.g. digalactosyl diglyceride (DGDG) or monogalactosyl diglyceride (MGDG)) with the lipolytic enzyme according to the present invention to produce the partial hydrolysis product, i.e. the lyso-glycolipid.
- DGMG digalactosyl monoglyceride
- MGDG monogalactosyl monoglyceride
- the present invention yet further provides the use of a lipolytic enzyme comprising any one of the amino acid sequences shown as SEQ ID No. 4, 5, 7, 8, 12, 14 or 16 or an amino acid sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97% or 98% identity therewith, or encoded by any one of the nucleotide sequences shown as SEQ ID No.
- a nucleotide sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97% or 98% identity therewith, in a foodstuff for the preparation of a lyso-phospholipid, for example lysolecithin, by treatment of a phospholipid (e.g. lecithin) with the enzyme to produce the partial hydrolysis product, i.e. a lyso-phospholipid.
- a phospholipid e.g. lecithin
- the present invention yet further provides the use of a lipolytic enzyme comprising any one of the amino acid sequences shown as SEQ ID No. 4, 5, 7, 8, 12, 14 or 16 or an amino acid sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97% or 98% identity therewith, or encoded by any one of the nucleotide sequences shown as SEQ ID No. 3, 6, 9, 13, 15 or 17 or a nucleotide sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97% or 98% identity therewith, in an egg or an egg-based product for the hydrolysis of phospholipids and/or glycolipids.
- a lipolytic enzyme comprising any one of the amino acid sequences shown as SEQ ID No. 4, 5, 7, 8, 12, 14 or 16 or an amino acid sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97% or 98% identity therewith, or encoded by any one of the nucleot
- the present invention provides the use of a lipolytic enzyme comprising any one of the amino acid sequences shown as SEQ ID No. 4, 5, 7, 8, 12, 14 or 16 or an amino acid sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97% or 98% identity therewith, or encoded by any one of the nucleotide sequences shown as SEQ ID No. 3, 6, 9, 13, 15 or 17 or a nucleotide sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97% or 98% identity therewith, in a substrate (preferably a foodstuff) for hydrolysing fatty acyl groups.
- a substrate preferably a foodstuff
- the present invention provides the use of a lipolytic enzyme comprising any one of the amino acid sequences shown as SEQ ED No. 4, 5, 7, 8, 12, 14 or 16 or an amino acid sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97% or 98% identity therewith, or encoded by any one of the nucleotide sequences shown as SEQ ID No. 3, 6, 9, 13, 15 or 17 or a nucleotide sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97% or 98% identity therewith, in an edible oil for reducing the content of a phospholipid.
- the present invention relates to the use of the lipolytic enzyme comprising any one of the amino acid sequences shown as SEQ ID No. 4, 5, 7, 8, 12, 14 or 16 or an amino acid sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97% or 98% identity therewith, or encoded by any one of the nucleotide sequences shown as SEQ ID No.
- a nucleotide sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97% or 98% identity therewith, in a substrate (preferably a bioconversion mixture comprising polar lipids (preferably glycolipids)) for the production of make high value products, such as carbohydrate esters and/or protein esters and/or protein subunit esters and/or a hydroxy acid ester.
- a substrate preferably a bioconversion mixture comprising polar lipids (preferably glycolipids)
- make high value products such as carbohydrate esters and/or protein esters and/or protein subunit esters and/or a hydroxy acid ester.
- the present invention relates to a lipolytic enzyme comprising any one of amino sequences shown as SEQ ED No. 8, 14 or 16 or an amino acid sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97% or 98% identity therewith for the uses described herein.
- the present invention relates to the use of a lipolytic enzyme comprising the amino acid sequence shown as SEQ ED No. 16 or an amino acid sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97% or 98% identity therewith.
- the present invention may provide a lipolytic enzyme capable of hydrolysing at least a glycolipid and/or capable of transferring an acyl group from at least a galactolipid to one or more acyl acceptors, wherein the enzyme is obtainable, preferably obtained, from Thermobifida spp, preferably T.fusca.
- the present invention may provide a lipolytic enzyme capable of hydrolysing at least a glycolipid and/or capable of transferring an acyl group from at least a galactolipid to one or more acyl acceptors, wherein the enzyme is obtainable, preferably obtained, from Corynebacterium spp, preferably C. efficiens.
- the present invention may provide a lipolytic enzyme capable of hydrolysing at least a glycolipid and/or capable of transferring an acyl group from at least a galactolipid to one or more acyl acceptors, wherein the enzyme is obtainable, preferably obtained, from Streptomyces avermitilis.
- the present invention may provide a lipolytic enzyme capable of hydrolysing at least a glycolipid and/or capable of transferring an acyl group from at least a galactolipid to one or more acyl acceptors, wherein the enzyme comprises SEQ
- the enzyme is encoded by any one of the nucleotide sequences shown as SEQ ID No. 6, 9, 13, or 17 or a nucleotide sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97% or
- the present invention may provide a lipolytic enzyme capable of hydrolysing at least a glycolipid and/or capable of transferring an acyl group from at least a galactolipid to one or more acyl acceptors, wherein the enzyme comprises SEQ ID No. 14 or an amino acid sequence which has at least 80%, 85%, 90%, 95%, 96%, 97% or 98% identity therewith, or the enzyme is encoded by any one of the nucleotide sequences shown as SEQ ED No. 15 or a nucleotide sequence which has at least 80%, 85%, 90%, 95%, 96%, 97% or 98% identity therewith.
- the present invention may provide a lipolytic enzyme capable of hydrolysing at least a glycolipid and/or capable of transferring an acyl group from at least a galactolipid to one or more acyl acceptors, wherein the enzyme comprises SEQ ID No. 16 or an amino acid sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97% or 98% identity therewith, or the enzyme is encoded by any one of the nucleotide sequences shown as SEQ ID No. 17 or a nucleotide sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97% or 98% identity therewith.
- the Streptomyces species from which the lipolytic enzyme is obtainable (or obtained) is not Streptomyces rimosus.
- the Streptomyces species from which the lipolytic enzyme is obtainable (or obtained) is not Streptomyces coelicolor.
- the lipolytic enzyme has significant glycolipid hydrolysing activity. This was surprising for a lipolytic enzyme from Streptomyces spp. In addition, this was surprising for a lipolytic enzyme from Thermobiflda and Corynebacterium spp.
- a further advantage of the present invention is that the lipolytic enzyme has no or no significant triacylglycerol hydrolysing activity.
- the sequence is in an isolated form.
- isolated means that the sequence is at least substantially free from at least one other component with which the sequence is naturally associated in nature and as found in nature.
- the sequence is in a purified form.
- purified means that the sequence is in a relatively pure state - e.g. at least about 90% pure, or at least about 95% pure or at least about 98% pure.
- the scope of the present invention encompasses nucleotide sequences encoding enzymes having the specific properties as defined herein.
- nucleotide sequence refers to an oligonucleotide sequence or polynucleotide sequence, and variants, homologues, fragments and derivatives thereof (such as portions thereof).
- the nucleotide sequence may be of genomic or synthetic or recombinant origin, which may be double-stranded or single-stranded whether representing the sense or anti-sense strand.
- nucleotide sequence in relation to the present invention includes genomic DNA, cDNA, synthetic DNA 5 and RNA. Preferably it means DNA, more preferably cDNA sequence coding for the present invention.
- the nucleotide sequence when relating to and when encompassed by the per se scope of the present invention does not include the native nucleotide sequence according to the present invention when in its natural environment and when it is linked to its naturally associated sequence(s) that is/are also in its/their natural environment.
- the term "non-native nucleotide sequence" means an entire nucleotide sequence that is in its native environment and when operatively linked to an entire promoter with which it is naturally associated, which promoter is also in its native environment.
- amino acid sequence encompassed by scope the present invention can be isolated and/or purified post expression of a nucleotide sequence in its native organism.
- amino acid sequence encompassed by scope of the present invention may be expressed by a nucleotide sequence in its native organism but wherein the nucleotide sequence is not under the control of the promoter with which it is naturally associated within that organism.
- nucleotide sequence encompassed by scope of the present invention is prepared using recombinant DNA techniques (i.e. recombinant DNA).
- recombinant DNA i.e. recombinant DNA
- the nucleotide sequence could be synthesised, in whole or in part, using chemical methods well known in the art (see Caruthers MH et al, (1980) Nuc Acids Res Symp Ser 215-23 and Horn T et al, (1980) Nuc Acids Res Symp Ser 225-232).
- a nucleotide sequence encoding an enzyme which has the specific properties as defined herein may be identified and/or isolated and/or purified from any cell or organism producing said enzyme.
- Various methods are well known within the art for the identification and/or isolation and/or purification of nucleotide sequences. By way of example, PCR amplification techniques to prepare more of a sequence may be used once a suitable sequence has been identified and/or isolated and/or purified.
- a genomic DNA and/or cDNA library may be constructed using chromosomal DNA or messenger RNA from the organism producing the enzyme. If the amino acid sequence of the enzyme or a part of the amino acid sequence of the enzyme is known, labelled oligonucleotide probes may be synthesised and used to identify enzyme-encoding clones from the genomic library prepared from the organism. Alternatively, a labelled oligonucleotide probe containing sequences homologous to another known enzyme gene could be used to identify enzyme- encoding clones. In the latter case, hybridisation and washing conditions of lower stringency are used.
- en2yme-encoding clones could be identified by inserting fragments of genomic DNA into an expression vector, such as a p ⁇ asmid, transforming enzyme- negative bacteria with the resulting genomic DNA library, and then plating the transformed bacteria onto agar plates containing a substrate for the enzyme (e.g. maltose for a glucosidase (maltase) producing enzyme), thereby allowing clones expressing the enzyme to be identified.
- an expression vector such as a p ⁇ asmid
- transforming enzyme- negative bacteria with the resulting genomic DNA library
- a substrate for the enzyme e.g. maltose for a glucosidase (maltase) producing enzyme
- the nucleotide sequence encoding the enzyme may be prepared synthetically by established standard methods, e.g. the phosphoroamidite method described by Beucage S.L. et al, (1981) Tetrahedron Letters 22, p 1859-1869, or the method described by Matthes et al, (1984) EMBO J. 3, p 801-805.
- the phosphoroamidite method oligonucleotides are synthesised, e.g. in an automatic DNA synthesiser, purified, annealed, ligated and cloned in appropriate vectors.
- the nucleotide sequence may be of mixed genomic and synthetic origin, mixed synthetic and cDNA origin, or mixed genomic and cDNA origin, prepared by ligating fragments of synthetic, genomic or cDNA origin (as appropriate) in accordance with standard techniques. Each ligated fragment corresponds to various parts of the entire nucleotide sequence.
- the DNA sequence may also be prepared by polymerase chain reaction (PCR) using specific primers, for instance as described in US 4,683,202 or in Saiki R K et al, ⁇ Science (1988) 239, pp 487-491).
- nucleotide sequences may be readily produced in which the triplet codon usage, for some or all of the amino acids encoded by the original nucleotide sequence, has been changed thereby producing a nucleotide sequence with low homology to the original nucleotide sequence but which encodes the same, or a variant, amino acid sequence as encoded by the original nucleotide sequence.
- nucleotide sequence in which all triplet codons have been "wobbled" in the third position would be about 66% identical to the original nucleotide sequence however, the amended nucleotide sequence would encode for the same, or a variant, primary amino acid sequence as the original nucleotide sequence.
- the present invention further relates to any nucleotide sequence that has alternative triplet codon usage for at least one amino acid encoding triplet codon, but which encodes the same, or a variant, polypeptide sequence as the polypeptide sequence encoded by the original nucleotide sequence.
- an enzyme-encoding nucleotide sequence has been isolated, or a putative enzyme-encoding nucleotide sequence has been identified, it may be desirable to modify the selected nucleotide sequence, for example it may be desirable to mutate the sequence in order to prepare an enzyme in accordance with the present invention.
- Mutations may be introduced using synthetic oligonucleotides. These oligonucleotides contain nucleotide sequences flanking the desired mutation sites.
- EP 0 583 265 refers to methods of optimising PCR based mutagenesis, which can also be combined with the use of mutagenic DNA analogues such as those described in EP 0 866 796. Error prone PCR technologies are suitable for the production of variants of lipolytic enzymes with preferred characteristics.
- WO0206457 refers to molecular evolution of lipases.
- a third method to obtain novel sequences is to fragment non-identical nucleotide sequences, either by using any number of restriction enzymes or an enzyme such as Dnase I, and reassembling full nucleotide sequences coding for functional proteins. Alternatively one can use one or multiple non-identical nucleotide sequences and introduce mutations during the reassembly of the full nucleotide sequence.
- DNA shuffling and family shuffling technologies are suitable for the production of variants of lipid acyl transferases with preferred characteristics. Suitable methods for performing 'shuffling' can be found in EPO 752 008, EPl 138 763, EPl 103 606. Shuffling can also be combined with other forms of DNA mutagenesis as described in US 6,180,406 and WO 01/34835.
- mutations or natural variants of a polynucleotide sequence can be recombined with either the wild type or other mutations or natural variants to produce new variants.
- Such new variants can also be screened for improved functionality of the encoded polypeptide.
- an enzyme may be altered to improve the functionality of the enzyme.
- the lipolytic enzyme used in the invention may be a variant, i.e. may contain at least one amino acid substitution, deletion or addition, when compared to a parental enzyme.
- Variant enzymes retain at least 20%, 30%, 40%, 50 %, 60%, 70%, 80%, 90%, 95%, 97%, 99% homology with the parent enzyme.
- Suitable parent enzymes may include any enzyme with esterase or lipase activity.
- the parent enzyme aligns to the pfamO0657 consensus sequence.
- a variant lipolytic enzyme retains or incorporates at least one or more of the pfam00657 consensus sequence amino acid residues found in the GDSx, GANDY and HPT blocks.
- Enzymes such as lipases with no or low galactolipase and/or phospholipase activity in an aqueous environment may be mutated using molecular evolution tools to introduce or enhance the galactolipase and/or phospholipase activity, thereby producing a lipolytic enzyme with significant galactolipase and/or phospholipase activity suitable for use in the compositions and methods of the present invention.
- the variant enzyme may have no activity on triglycerides and/or monoglycerides and/or diglycerides.
- the variant enzyme for use in the invention may have increased activity on triglycerides, and/or may also have increased activity on one or more of the following, polar lipids, phospholipids, lecithin, phosphatidylcholine, glycolipids, digalactosyl monoglyceride, monogalactosyl monoglyceride.
- amino acid sequence is synonymous with the term “polypeptide” and/or the term “protein”. In some instances, the term “amino acid sequence” is synonymous with the term “peptide”. In some instances, the term “amino acid sequence” is synonymous with the term “enzyme”.
- amino acid sequence may be prepared/isolated from a suitable source, or it may be made synthetically or it may be prepared by use of recombinant DNA techniques.
- the enzyme encompassed in the present invention may be used in conjunction with other enzymes.
- the present invention also covers a combination of enzymes wherein the combination comprises the enzyme of the present invention and another enzyme, which may be another enzyme according to the present invention. This aspect is discussed in a later section.
- amino acid sequence when relating to and when encompassed by the per se scope of the present invention is not a native enzyme.
- native enzyme means an entire enzyme that is in its native environment and when it has been expressed by its native nucleotide sequence.
- the present invention also encompasses the use of homologues of any amino acid sequence of an enzyme or of any nucleotide sequence encoding such an enzyme.
- homologue means an entity having a certain homology with the amino acid sequences and the nucleotide sequences.
- homology can be equated with “identity”.
- a homologous amino acid sequence is taken to include an amino acid sequence which may be at least 87 or 90% identical, preferably at least 95, 96, 97, 98 or 99% identical to the sequence.
- the homologues will comprise the same active sites etc. — e.g. as the subject amino acid sequence.
- homology can also be considered in terms of similarity (i.e. amino acid residues having similar chemical properties/functions), in the context of the present invention it is preferred to express homology in terms of sequence identity.
- an homologous nucleotide sequence is taken to include a nucleotide sequence which may be at least 85 or 90% identical, preferably at least 95, 96, 97, 98 or 99% identical to a nucleotide sequence encoding an enzyme of the present invention (the subject sequence).
- the homologues will comprise the same sequences that code for the active sites etc. as the subject sequence.
- homology can also be considered in terms of similarity (i.e. amino acid residues having similar chemical properties/functions), in the context of the present invention it is preferred to express homology in terms of sequence identity.
- homology comparisons can be conducted by eye, or more usually, with the aid of readily available sequence comparison programs. These commercially available computer programs can calculate % homology between two or more sequences. % homology may be calculated over contiguous sequences, i.e. one sequence is aligned with the other sequence and each amino acid in one sequence is directly compared with the corresponding amino acid in the other sequence, one residue at a time. This is called an "ungapped" alignment. Typically, such ungapped alignments are performed only over a relatively short number of residues.
- BLAST Altschul et al, 1999 Short Protocols in Molecular Biology, 4 th Ed - Chapter 18
- FASTA Altschul et al, 1990 J. MoI. Biol. 403-410
- GENEWORKS GENEWORKS suite of comparison tools. Both BLAST and FASTA are available for offline and online searching (see Ausubel et al., 1999, Short Protocols in Molecular Biology, pages 7-58 to 7-60).
- GCG Bestfit program A new tool, called BLAST 2 Sequences is also available for comparing protein and nucleotide sequence (see FEMS Microbiol Lett 1999 174(2): 247-50; and FEMS Microbiol Lett 1999 177(1): 187-8).
- a scaled similarity score matrix is generally used that assigns scores to each pairwise comparison based on chemical similarity or evolutionary distance.
- An example of such a matrix commonly used is the BLOSUM62 matrix - the default matrix for the BLAST suite of programs.
- GCG Wisconsin programs generally use either the public default values or a custom symbol comparison table if supplied (see user manual for further details). For some applications, it is preferred to use the public default values for the GCG package, or in the case of other software, the default matrix, such as BLOSUM62.
- percentage homologies may be calculated using the multiple alignment feature in DNASISTM (Hitachi Software), based on an algorithm, analogous to CLUSTAL (Higgins DG & Sharp PM (1988), Gene 73(1), 237-244).
- % homology preferably % sequence identity.
- the software typically does this as part of the sequence comparison and generates a numerical result.
- percentage sequence homology/identity are used. For amino acid sequences percentage of identities (homology) or "positives" are calculated by the AlignX VectorlSm (Vector NTI Advance 9.1 from Invitrogen Corporation, Carlsbad, California, USA.) for each possible pair of amino acid sequences. Settings are default parameters (Gap opening penalty - 10, Gap extension penalty 0.1).
- nucleic acid sequences percentage of identities (homology) or "positives" are calculated by the AlignX VectorNTI programme from Inforrnax Inc. (USA) for each possible pair of nucleic acid sequences. Settings are default settings which for DNA is: Gap opening penalty: 15 and Gap extension penalty: 6.66. (same settings for multiple alignments).
- amino acid identity is calculated across the full-length amino acid sequence (e.g. SEQ IDs 4, 5, 7, 8, 10, 12 and 14), or for nucleic acid to a corresponding polynucleotide which encodes the respective the full-length amino acid sequence.
- Amino acid or nucleic acid identity may be, preferably, calculated by comparing the homology/identity over the mature polypeptide sequence, i.e. a polypeptide sequence which has been co- or post-translationally processed, for example by cleavage of an N-terminal signal peptide, or a C-terminal cleavage event.
- sequences may also have deletions, insertions or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent substance.
- Deliberate amino acid substitutions may be made on the basis of similarity in amino acid properties (such as polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues) and it is therefore useful to group amino acids together in functional groups.
- Amino acids can be grouped together based on the properties of their side chain alone. However it is more useful to include mutation data as well.
- the sets of amino acids thus derived are likely to be conserved for structural reasons. These sets can be described in the form of a Venn diagram (Livingstone CD. and Barton GJ.
- the present invention also encompasses homologous substitution (substitution and replacement are both used herein to mean the interchange of an existing amino acid residue, with an alternative residue) that may occur i.e. like-for-like substitution such as basic for basic, acidic for acidic, polar for polar etc.
- Non-homologous substitution may also occur i.e.
- Z ornithine
- B diaminobutyric acid ornithine
- O norleucine ornithine
- pyriylalanine thienylalanine
- naphthylalanine phenylglycine
- Replacements may also be made by unnatural amino acids.
- Variant amino acid sequences may include suitable spacer groups that may be inserted between any two amino acid residues of the sequence including alkyl groups such as methyl, ethyl or propyl groups in addition to amino acid spacers such as glycine or ⁇ - alanine residues.
- alkyl groups such as methyl, ethyl or propyl groups
- amino acid spacers such as glycine or ⁇ - alanine residues.
- a further form of variation involves the presence of one or more amino acid residues in peptoid form, and will be well understood by those skilled in the art.
- the peptoid form is used to refer to variant amino acid residues wherein the ⁇ -carbon substituent group is on the residue's nitrogen atom rather than the ⁇ -carbon.
- the nucleotide sequences for use in the present invention may include within them synthetic or modified nucleotides.
- a number of different types of modification to oligonucleotides are known in the art. These include methylphosphonate and phosphorothioate backbones and/or the addition of acridine or polylysine chains at the 3' and/or 5' ends of the molecule.
- the nucleotide sequences described herein may be modified by any method available in the art. Such modifications may be carried out in order to enhance the in vivo activity or life span of nucleotide sequences of the present invention.
- the present invention also encompasses the use of nucleotide sequences that are complementary to the sequences presented herein, or any derivative, fragment or derivative thereof. If the sequence is complementary to a fragment thereof then that sequence can be used as a probe to identify similar coding sequences in other organisms etc.
- Polynucleotides which are not 100% homologous to the sequences of the present invention but fall within the scope of the invention can be obtained in a number of ways.
- Other variants of the sequences described herein may be obtained for example by probing DNA libraries made from a range of individuals, for example individuals from different populations.
- other homologues may be obtained and such homologues and fragments thereof in general will be capable of selectively hybridising to the sequences shown in the sequence listing herein.
- Such sequences may be obtained by probing cDNA libraries made from or genomic DNA libraries from other species, and probing such libraries with probes comprising all or part of any one of the sequences in the attached sequence listings under conditions of medium to high stringency. Similar considerations apply to obtaining species homologues and allelic variants of the polypeptide or nucleotide sequences of the invention.
- Variants and strain/species homologues may also be obtained using degenerate PCR which will use primers designed to target sequences within the variants and homologues encoding conserved amino acid sequences within the sequences of the present invention.
- conserveed sequences can be predicted, for example, by aligning the amino acid sequences from several variants/homologues. Sequence alignments can be performed using computer software known in the art. For example the GCG Wisconsin PiIeUp program is widely used.
- the primers used in degenerate PCR will contain one or more degenerate positions and will be used at stringency conditions lower than those used for cloning sequences with single sequence primers against known sequences.
- polynucleotides may be obtained by site directed mutagenesis of characterised sequences. This may be useful where for example silent codon sequence changes are required to optimise codon preferences for a particular host cell in which the polynucleotide sequences are being expressed. Other sequence changes may be desired in order to introduce restriction enzyme recognition sites, or to alter the property or function of the polypeptides encoded by the polynucleotides.
- Polynucleotides (nucleotide sequences) of the invention may be used to produce a primer, e.g. a PCR primer, a primer for an alternative amplification reaction, a probe e.g. labelled with a revealing label by conventional means using radioactive or non-radioactive labels, or the polynucleotides may be cloned into vectors.
- a primer e.g. a PCR primer, a primer for an alternative amplification reaction, a probe e.g. labelled with a revealing label by conventional means using radioactive or non-radioactive labels, or the polynucleotides may be cloned into vectors.
- Such primers, probes and other fragments will be at least 15, preferably at least 20, for example at least 25, 30 or 40 nucleotides in length, and are also encompassed by the term polynucleotides of the invention as used herein.
- primers will be produced by synthetic means, involving a stepwise manufacture of the desired nucleic acid sequence one nucleotide at a time. Techniques for accomplishing this using automated techniques are readily available in the art
- Longer polynucleotides will generally be produced using recombinant means, for example using a PCR (polymerase chain reaction) cloning techniques.
- the primers may be designed to contain suitable restriction enzyme recognition sites so that the amplified DNA can be cloned into a suitable cloning vector.
- the variant sequences etc. are at least as biologically active as the sequences presented herein.
- biologically active refers to a sequence having a similar structural function (but not necessarily to the same degree), and/or similar regulatory function (but not necessarily to the same degree), and/or similar biochemical function (but not necessarily to the same degree) of the naturally occurring sequence.
- the present invention also encompasses sequences that are complementary to the nucleic acid sequences of the present invention or sequences that are capable of hybridising either to the sequences of the present invention or to sequences that are complementary thereto.
- hybridisation shall include "the process by which a strand of nucleic acid joins with a complementary strand through base pairing" as well as the process of amplification as carried out in polymerase chain reaction (PCR) technologies.
- the present invention also encompasses the use of nucleotide sequences that are capable of hybridising to the sequences that are complementary to the sequences presented herein, or any derivative, fragment or derivative thereof.
- variant also encompasses sequences that are complementary to sequences that are capable of hybridising to the nucleotide sequences presented herein.
- the present invention also relates to nucleotide sequences that can hybridise to the nucleotide sequences of the present invention (including complementary sequences of those presented herein).
- the present invention also relates to nucleotide sequences that are complementary to sequences that can hybridise to the nucleotide sequences of the present invention (including complementary sequences of those presented herein). Also included within the scope of the present invention are polynucleotide sequences that are capable of hybridising to the nucleotide sequences presented herein under conditions of intermediate to maximal stringency.
- the present invention covers nucleotide sequences that can hybridise to the nucleotide sequence of the present invention, or the complement thereof, under stringent conditions (e.g. 5O 0 C and 0.2xSSC).
- stringent conditions e.g. 5O 0 C and 0.2xSSC.
- the present invention covers nucleotide sequences that can hybridise to the nucleotide sequence of the present invention, or the complement thereof, under high stringent conditions (e.g. 65 0 C and 0. IxSSC).
- high stringent conditions e.g. 65 0 C and 0. IxSSC.
- sequence for use in the present invention is a recombinant sequence — Le. a sequence that has been prepared using recombinant DNA techniques.
- sequence for use in the present invention is a synthetic sequence - i.e. a sequence that has been prepared by in vitro chemical or enzymatic synthesis. It includes, but is not limited to, sequences made with optimal codon usage for host organisms - such as the methylotrophic yeasts Pichia and Hansenula. EXPRESSION OF ENZYMES
- the nucleotide sequence for use in the present invention may be incorporated into a recombinant replicable vector.
- the vector may be used to replicate and express the nucleotide sequence, in enzyme form, in and/or from a compatible host cell.
- Expression may be controlled using control sequences e.g. regulatory sequences.
- the enzyme produced by a host recombinant cell by expression of the nucleotide sequence may be secreted or may be contained intracellulariy depending on the sequence and/or the vector used.
- the coding sequences may be designed with signal sequences which direct secretion of the substance coding sequences through a particular prokaryotic or eukaryotic cell membrane.
- expression vector means a construct capable of in vivo or in vitro expression.
- the expression vector is incorporated into the genome of a suitable host organism.
- the term "incorporated” preferably covers stable incorporation into the genome.
- the nucleotide sequence of the present invention may be present in a vector in which the nucleotide sequence is operably linked to regulatory sequences capable of providing for the expression of the nucleotide sequence by a suitable host organism.
- the vectors for use in the present invention may be transformed into a suitable host cell as described below to provide for expression of a polypeptide of the present invention.
- vector e.g. a plasmid, cosmid, or phage vector
- the choice of vector e.g. a plasmid, cosmid, or phage vector will often depend on the host cell into which it is to be introduced.
- the vectors for use in the present invention may contain one or more selectable marker genes- such as a gene, which confers antibiotic resistance e.g. ampicillin, kanamycin, chloramphenicol or tetracyclin resistance.
- the selection may be accomplished by co-transformation (as described in WO91/17243).
- Vectors may be used in vitro, for example for the production of RNA or used to transfect, transform, transduce or infect a host cell.
- the invention provides a method of making nucleotide sequences of the present invention by introducing a nucleotide sequence of the present invention into a replicable vector, introducing the vector into a compatible host cell, and growing the host cell under conditions which bring about replication of the vector.
- the vector may further comprise a nucleotide sequence enabling the vector to replicate in the host cell in question.
- sequences are the origins of replication of plasmids pUC19, pACYC177, pUBl 10, pE194, pAMBl and pIJ702.
- the nucleotide sequence for use in the present invention is operably linked to a regulatory sequence which is capable of providing for the expression of the nucleotide sequence, such as by me chosen host cell.
- a regulatory sequence which is capable of providing for the expression of the nucleotide sequence, such as by me chosen host cell.
- the present invention covers a vector comprising the nucleotide sequence of the present invention operably linked to such a regulatory sequence, i.e. the vector is an expression vector.
- operably linked refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner.
- a regulatory sequence "operably linked” to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under condition compatible with the control sequences.
- regulatory sequences includes promoters and enhancers and other expression regulation signals.
- promoter is used in the normal sense of the art, e.g. an RNA polymerase binding site.
- Enhanced expression of the nucleotide sequence encoding the enzyme of the present invention may also be achieved by the selection of heterologous regulatory regions, e.g. promoter, secretion leader and terminator regions.
- heterologous regulatory regions e.g. promoter, secretion leader and terminator regions.
- the nucleotide sequence according to the present invention is operably linked to at least a promoter.
- Suitable promoters for directing the transcription of the nucleotide sequence in a bacterial, fungal or yeast host are well known in the art.
- construct which is synonymous with terms such as “conjugate”, “cassette” and “hybrid” - includes a nucleotide sequence for use according to the present invention directly or indirectly attached to a promoter.
- an indirect attachment is the provision of a suitable spacer group such as an intron sequence, such as the Shl-intron or the ADH intron, intermediate the promoter and the nucleotide sequence of the present invention.
- a suitable spacer group such as an intron sequence, such as the Shl-intron or the ADH intron, intermediate the promoter and the nucleotide sequence of the present invention. The same is true for the term
- the terms do not cover the natural combination of the nucleotide sequence coding for the protein ordinarily associated with the wild type gene promoter and when they are both in their natural environment.
- the construct may even contain or express a marker, which allows for the selection of the genetic construct.
- the construct of the present invention comprises at least the nucleotide sequence of the present invention operably linked to a promoter.
- host cell in relation to the present invention includes any cell that comprises either the nucleotide sequence or an expression vector as described above and which is used in the recombinant production of an enzyme having the specific properties as defined herein.
- a further embodiment of the present invention provides host cells transformed or transfected with a nucleotide sequence that expresses the enzyme of the present invention.
- the cells will be chosen to be compatible with the said vector and may for example be prokaryotic (for example bacterial), fungal, yeast or plant cells.
- the host cells are not human cells.
- Suitable bacterial host organisms are gram positive or gram negative bacterial species.
- eukaryotic hosts such as yeasts or other fungi may be preferred.
- yeast cells are preferred over fungal cells because they are easier to manipulate.
- yeast, fungal and plant host cells - may provide for post-translational modifications (e.g. myristoylation, glycosylation, truncation, lapidation and tyrosine, serine or threonine phosphorylation) as may be needed to confer optimal biological activity on recombinant expression products of the present invention.
- the host cell may be a protease deficient or protease minus strain.
- the genotype of the host cell may be modified to improve expression.
- host cell modifications include protease deficiency, supplementation of rare tRNA's, and modification of the reductive potential in the cytoplasm to enhance disulphide bond formation.
- the host cell E. coli may overexpress rare tRNA's to improve expression of heterologous proteins as exemplified/described in Kane (Curr Opin Biotechnol (1995), 6, 494-500 "Effects of rare codon clusters on high-level expression of heterologous proteins in E.colf).
- the host cell may be deficient in a number of reducing enzymes thus favouring formation of stable disulphide bonds as exemplified/described in Bessette (Proc Natl Acad Sci USA (1999), 96, 13703-13708 " Efficient folding of proteins with multiple disulphide bonds in the Escherichia coli cytoplasm").
- the host cell is a bacteria, preferably a gram-positive bacteria, preferably a host cell selected from Actinobacteria, such as Bifidobacteria and Aeromonas, particularly preferably Aeromonas salmonicida. Still more preferred are Actinomicetales such as Corynebacteria, in particular Corynebacterium glutamicum and Nocardia. Particularly preferred are Streptomycetaceae, such as Streptomyces, especially S. lividans.
- Actinobacteria such as Bifidobacteria and Aeromonas, particularly preferably Aeromonas salmonicida.
- Actinomicetales such as Corynebacteria, in particular Corynebacterium glutamicum and Nocardia.
- Streptomycetaceae such as Streptomyces, especially S. lividans.
- a microbial host can be used for expression of the galactolipase gene, e.g. Eubacteria, Archea or Fungi, including yeast.
- Eubacteria for example, Firmicutes (low GC-Gram positive bacteria), such as Bacillus subtilis and other bacillus species, lactic acid bacteria such as species of genera Lactobacillus and Lactococcus.
- Gram-negative Proteobacteria in particular Gammaproteobacteria, such as host species belonging to the genera Pseudomonas, Xanthomonas, Citrobacter and Escherichia, especially Escherichia coli.
- the host cell is the same genus as the native host species, i.e. the recombinant gene is re-introduced and expressed in a species from the same genus as the species from which the recombinant gene was isolated.
- the host cell is the native host species, i.e. the recombinant gene is re-introduced and expressed in the same species from which the recombinant gene was isolated.
- organism in relation to the present invention includes any organism that could comprise the nucleotide sequence coding for the enzyme according to the present invention and/or products obtained therefrom, and/or wherein a promoter can allow expression of the nucleotide sequence according to the present invention when present in the organism.
- Suitable organisms may include a prokaryote, fungus, yeast or a plant.
- transgenic organism in relation to the present invention includes any organism that comprises the nucleotide sequence coding for the enzyme according to the present invention and/or the products obtained therefrom, and/or wherein a promoter can allow expression of the nucleotide sequence according to the present invention within the organism.
- the nucleotide sequence is incorporated in the genome of the organism.
- transgenic organism does not cover native nucleotide coding sequences in their natural environment when they are under the control of their native promoter which is also in its natural environment
- the transgenic organism of the present invention includes an organism comprising any one of, or combinations of, the nucleotide sequence coding for the enzyme according to the present invention, constructs according to the present invention, vectors according to the present invention, plasmids according to the present invention, cells according to the present invention, tissues according to the present invention, or the products thereof.
- transgenic organism may also comprise the nucleotide sequence coding for the enzyme of the present invention under the control of a heterologous promoter.
- the host organism can be a prokaryotic or a eukaryotic organism.
- suitable prokaryotic hosts include E. coli and Bacillus subtilis.
- Filamentous fungi cells may be transformed using various methods known in the art — such as a process involving protoplast formation and transformation of the protoplasts followed by regeneration of the cell wall in a manner known.
- Aspergillus as a host microorganism is described in EP 0 238 023.
- Another host organism can be a plant.
- a review of the general techniques used for transforming plants may be found in articles by Potrykus (Annu Rev Plant Physiol Plant MoI Biol [1991] 42:205-225) and Christou (Agro-Food-Industry Hi-Tech March/April 1994 17-27). Further teachings on plant transformation may be found in EP-A-0449375.
- a host organism may be a fungus - such as a filamentous fungus.
- suitable such hosts include any member belonging to the genera Thermomyces, Acremonium, Aspergillus, Penicillium, Mucor, Neurospora, Trichoderma and the like.
- the host organism can be of the genus Aspergillus, such as Aspergillus niger.
- a transgenic Aspergillus according to the present invention can also be prepared by following, for example, the teachings of Turner G. 1994 (Vectors for genetic manipulation. In: Martinelli S.D., Kinghorn J.R.( Editors) Aspergillus: 50 years on. Progress in industrial microbiology vol 29. Elsevier Amsterdam 1994. pp. 641-666). Gene expression in filamentous fungi has been reviewed in Punt et a (2002) Trends Biotechnol 2002 May;20(5):200-6, Archer & Peberdy Crit Rev Biotechnol (1997) 17(4):273-306.
- the transgenic organism can be a yeast.
- yeast - such as the species Saccharomyces cereviseae or Pichia pastoris (see FEMS Microbiol Rev (2000 24(l):45-66), may be used as a vehicle for heterologous gene expression.
- transgenic Saccharomyces can be prepared by following the teachings of Hinnen et al., (1978, Proceedings of the National Academy of Sciences of the USA 75, 1929); Beggs, J D (1978, Nature, London, 275, 104); and Ito, H et al (1983, J Bacteriology 153, 163-168).
- the transformed yeast cells may be selected using various selective markers - such as auxotrophic markers dominant antibiotic resistance markers.
- a host organism suitable for the present invention may be a plant.
- a review of the general techniques may be found in articles by Potrykus (Annu Rev Plant Physiol Plant MoI Biol [1991] 42:205-225) and Christou (Agro-Food-Industry HI-Tech March/April 1994 17-27).
- Host cells transformed with the nucleotide sequence of the present invention may be cultured under conditions conducive to the production of the encoded enzyme and which facilitate recovery of the enzyme from the cells and/or culture medium.
- the medium used to cultivate the cells may be any conventional medium suitable for growing the host cell in questions and obtaining expression of the enzyme.
- the protein produced by a recombinant cell may be displayed on the surface of the cell.
- the enzyme may be secreted from the host cells and may conveniently be recovered from the culture medium using well-known procedures.
- the enzyme may be secreted from the expression host into the culture medium from where the enzyme may be more easily recovered.
- the secretion leader sequence may be selected on the basis of the desired expression host.
- Hybrid signal sequences may also be used with the context of the present invention.
- heterologous secretion leader sequences are those originating from the fungal amyloglucosidase (AG) gene (glaA - both 18 and 24 amino acid versions e.g. from Aspergillus), the a-factor gene (yeasts e.g. Saccharomyces, KJuyveromyces and Hansenul ⁇ ) or the ⁇ -amylase gene (Bacillus).
- AG fungal amyloglucosidase
- glaA both 18 and 24 amino acid versions e.g. from Aspergillus
- a-factor gene e.g. Saccharomyces, KJuyveromyces and Hansenul ⁇
- ⁇ -amylase gene Bacillus
- ELISA enzyme-linked immunosorbent assay
- RIA radioimmunoassay
- FACS fluorescent activated cell sorting
- Suitable reporter molecules or labels include those radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles and the like. Patents teaching the use of such labels include US-A-3,817,837; US-A-3,850,752; US-A-3,939,350; US-A-3, 996,345; US-A- 4,277,437; US-A-4,275,149 and US-A-4,366,241.
- recombinant immunoglobulins may be produced as shown in US-A-4,816,567.
- the amino acid sequence for use according to the present invention may be produced as a fusion protein, for example to aid in extraction and purification.
- fusion protein partners include glutathione-S-transferase (GST) 3 6xHis, GAL4 (DNA binding and/or transcriptional activation domains) and ( ⁇ -galactosidase). It may also be convenient to include a proteolytic cleavage site between the fusion protein partner and the protein sequence of interest to allow removal of fusion protein sequences.
- the fusion protein will not hinder the activity of the protein sequence.
- the amino acid sequence may be ligated to a heterologous sequence to encode a fusion protein.
- a heterologous sequence for example, for screening of peptide libraries for agents capable of affecting the substance activity, it may be useful to encode a chimeric substance expressing a heterologous epitope that is recognised by a commercially available antibody.
- the amino acid sequence is used for large scale applications.
- amino acid sequence is produced in a quantity of from Ig per litre to about 2g per litre of the total cell culture volume after cultivation of the host organism.
- amino acid sequence is produced in a quantity of from lOOmg per litre to about 900mg per litre of the total cell culture volume after cultivation of the host organism.
- amino acid sequence is produced in a quantity of from 250mg per litre to about 500mg per litre of the total cell culture volume after cultivation of the host organism.
- composition of the present invention may be used as — or in the preparation of - a food.
- the term "food” is used in a broad sense - and covers food for humans as well as food for animals (i.e. a feed). In a preferred aspect, the food is for human consumption.
- the food may be in the form of a solution or as a solid - depending on the use and/or the mode of application and/or the mode of administration.
- composition of the present invention may be used as a food ingredient.
- food ingredient* ' includes a formulation, which is or can be added to functional foods or foodstuffs and includes formulations which can be used at low levels in a wide variety of products that require, for example, acidifying or emulsifying.
- the food ingredient may be in the form of a solution or as a solid - depending on the use and/or the mode of application and/or the mode of administration.
- composition of the present invention can be used in the preparation of food products such as one or more of: confectionery products, dairy products, meat products, poultry products, fish products and bakery products.
- the present invention also provides a method of preparing a food or a food ingredient, the method comprising admixing a lipolytic enzyme according to the present invention with another food ingredient. Further preferable aspects are presented in the accompanying claims and in the following Figures and examples.
- Figure 1 shows PCR fragment SEQ ID No. 1, which is a partial non-enzyme encoding polynucleotide; this sequence is a ribosomal 16S RNA gene widely used for taxonomic comparisons;
- Figure 2 shows PCR fragment SEQ ID No. 2, which is a partial non-enzyme encoding polynucleotide; this sequence is a ribosomal 16S RNA gene widely used for taxonomic comparisons;
- Figure 3 shows a polynucleotide encoding a lipolytic enzyme according to the present invention (SEQ ID No. 3);
- Figure 4 shows an amino acid sequence of a lipolytic enzyme according to the present invention (SEQ ID No. 4);
- Figure 5 shows the structure of the lipolytic enzyme expression vectors pGTK(L131) and pETll(131-51);
- Figure 6 shows a graph of the effect of a lipolytic enzyme from Streptomyces sp. L130 on digalactosyldiglyceride in dough;
- Figure 7 shows in graphical form the effect of a lipolytic enzyme from Streptomyces sp. Ll 31 on digalactosyldiglyceride in dough;
- Figure 8 shows in graphical form the effect of a lipolytic enzyme from Streptomyces on triglyceride in dough
- Figure 9 shows the pH profile of the lipolytic enzyme obtained from Streptomyces sp. Ll 31 on galactolipid substrate
- Figure 11 shows the construction of expression vector pRX487 from pUC18(L131R) and pIJ48;
- Figure 12 shows in graphical form the effect of temperature on stability and activity of a lipolytic enzyme from Streptomyces sp L131 ;
- Figure 13 shows in graphical form the substrate specificities of galactolipases from Streptomyces sp L131, Streptomyces avermitillis, Corynebacterium efficiens and Thermobifldafasca;
- Figure 14 shows the structure of an expression vector pCB5(TF) for expression of Thermobifidafiisca lipase in C. glutamicum;
- Figure 15 shows a sequence alignment of L131 and homologues S. avermitilis and T. fiisca;
- Figure 16 shows a HPTLC plate of reaction products from enzyme treatment of crude soya oil samples.
- Lane 1 control
- Lane 2 99% crude oil and 1% K371 10% in water
- Lane 3 98% crude oil and 2% K371 10% in water
- Lane 4 97% crude oil and 3% K371 10% in water
- Lane 5 99.7% crude oil and 0.3% Lecitase UltraTM #3108 1% in water
- Lane 6 99% crude oil, 0.3% Lecitase UltraTM #3108 1% in water and 0.7% water.
- PC phoshpatidylcholine
- Figure 17 shows a HPTLC plate of reaction products from enzyme treatment of crude soya oil samples.
- Lane 1 control
- Lane 2 99% crude oil and 1% K371 10% in water
- Lane 3 98% crude oil and 2% K371 10% in water
- Lane 4 97% crude oil and 3% K371 10% in water
- Lane 5 99.7% crude oil and 0.3% Lecitase UltraTM #3108 1% in water
- Lane 6 99% crude oil, 0.3% Lecitase UltraTM #3108 1% in water and 0.7% water, together with reference lanes of cholesterol ester, monoglyceride, diglyceride, triglyceride and plant sterol.
- Example 1 Identification of a galactolipase producing bacterial strain.
- SEQ E) No.s 1 and 2 are nonenzyme encoding polynucleotides. These sequences are ribosomal 16S RNA genes widely used for taxonomic comparisons. SEQ ID No. 1 and SEQ ID No. 2 were found to have a high similarity. The sequences were then compared to the 16S RNA gene sequences in GenBank. For both isolates the highest homology (97%) was observed with the sequence of a 16S RNA gene from Streptomyces thermosacchari. Thus, the strains were named Streptomyces sp. L130 and Streptomyces sp. L131.
- Example 2 Preparation of lipolytic enzyme (galactolipase) samples from strains Streptomyces sp. Ll 30 and L131.
- 0.5 1 of LB medium was inoculated with Streptomyces L130 and cultivated on a rotary shaker at 200 rpm and 3O 0 C for 2 days. This culture was used as inoculum for a 10 1 fermentor containing the same medium. The cultivation was continued for 3 days at 3O 0 C, 600 rpm stirring rate and 0.5 v/v aeration. The fermentation broth was cleared by centrifugation (15 min at 5000 rpm) and Triton X-100 was added to final concentration of 0.1%. The solution was concentrated using Vivaflow 200 ultrafiltration cell (Vivascience AG, Hannover, Germany) to 300 ml.
- the concentrate was dialysed against 10 1 of 20 mM Tris HCl buffer, pH 7 containing 2 mM CaCl 2 and 2 mM MgCl 2 followed by dialysis against 0.5 1 ml of 85% glycerol.
- the resulting preparations contained 90 U of galactolipase activity assay as defined above (GLU-7).
- the strain Streptomyces Ll 31 was cultivated under the same conditions and its culture broth was concentrated by the same procedure.
- the resulting galactolipase preparation contained 7OU of activity.
- the galactolipases from bacterial isolates L130 and L131 indicated a high activity on polar lipid substrates, galactolipids (DGDG) and phospholipids, (galactolipase and phospholipase activity), equivalent to that of a Fusarium oxysporum lipase (Lipopan FTM Novozymes A/S Denmark): however the galactolipase from bacterial isolates L130 and L131 (Le. the lipolytic enzyme according to the present invention) were found to have no significant activity of triglycerides. This contrasts sharply with the activity Fusarium oxysporum lipase - LipopanFTM.
- the lipolytic enzymes from bacterial isolates L 130 and L131 were prepared as described in Example 2 and were analysed for characterisation of their activity on glycolipids, phospholipids and triglycerides, both in standard assay conditions and within a dough.
- the phospholipase and galactolipase activity of the enzymes were assessed using the phospholipase activity assay (PLU-7) and the galactolipase activity assay (GLU-7) mentioned herein above.
- the sample was then centrifuged at 2000 g for 10 minutes. And 2 ml supernatant was transferred to a 10 ml dram glass. The solvent was evaporated at 70 0 C under a steam of nitrogen. The isolated lipids are analysed by GLC.
- Perkin Elmer 8420 Capillary Gas Chromatography equipped with WCOT fused silica column 12.5 m x 0.25 mm ID x 0.1 ⁇ m 5%phenyl-methyl-silicone (CP SiI 8 CB from Crompack). Carrier: Helium. Injection: 1.5 ⁇ L with split. Detector: FID. 385 0 C.
- Sample preparation Lipid extracted from 0,2 gram flour was dissolved in 2 mL heptane: pyridine 2:1 containing an internal standard heptadecane, 2 mg/mL. 500 ⁇ L of the sample was transferred to a crimp vial. 100 ⁇ L MSTFA (N-Methyl-N- trimethylsilyl-trifluoracetamid) was added and the reaction incubated for 15 minutes at 90 0 C.
- MSTFA N-Methyl-N- trimethylsilyl-trifluoracetamid
- results from table 3 and table 4 confirm that the enzymes isolated in the supernatant from fermentation of Streptomyces sp Ll 30 and Ll 31 are very active on galactolipids in a dough.
- the diesters DGDG and MGDG are hydrolyzed to the corresponding monoesters DGMG and MGMG.
- the results are also illustrated graphically in Figures 6 and 7. These results confirm that both enzymes are very active at low dosage 0-0.2 Units/g flour and corresponding amount of monoester is produced. At higher dosage 0,4-1 Units/gram flour DGDG is further degraded but also some hydrolysis of the monoesters are observed. This may indicate the enzymes are not specific to the position of the fatty acid in the galactolipid molecule.
- a lipolytic enzyme was isolated in the supernatant from fermentation of Streptomyces sp.
- the lipolytic enzyme was found to have both phospholipase and galactolipase activity, but no significant activity on triglycerides.
- the ratio of phospholipase: galactolipase activity was approx. 1.4 for the samples tested.
- Dough slurry experiments confirms that the enzymes were active on galactolipids in the flour.
- the enzymes were active in dough at a very low dosage 0-0.2 Units/g flour.
- Commercial phospholipases like Lipopan FTM Novopan FTM (Novozymes A/S, Denmark) need to be dosed in 3-4 times higher dosage in order to obtain the same effect on galactolipids.
- the dough slurry experiments also confirmed that the enzymes from Streptomyces sp. had no measurable activity on triglycerides.
- Example 4 Cloning of the lipolytic enzyme gene from Streptomyces sp. L131.
- the chromosomal DNA was isolated from Streptomyces sp. Ll 31 using a modification of a standard method. Bacteria were grown on a rotary shaker in LB medium at 30 0 C and high aeration (100 ml of medium per 0.51 baffled flask, 200 rpm) to early stationary phase. From 500 ml bacterial culture cells were collected with centrifugation and washed once with lysis buffer (550 mM glucose, 100 mM Tris, 2 mM EDTA, pH 8.0).
- lysis buffer 550 mM glucose, 100 mM Tris, 2 mM EDTA, pH 8.0.
- Cell pellet was re-suspended in 10 ml of lysis buffer and lysozyme was added to 1 mg/ml. Cells were incubated at 37°C for at least 15 min. The progress of lysozyme digestion was followed by transferring aliquots of bacterial suspension into 1% SDS solution and measuring the absorption of the resulting mixture at 600 nm. The amount of lysozyme and incubation time were adjusted so that at least 70-90% of all cells were lysed as evidenced by the decrease in A 6 oo- At this point of time, SDS was added to the bacterial suspension to 1% and proteinase K to 0.1 mg/ml.
- RNAse A (0.01 mg/ml).
- the DNA was partially digested with restriction endonuclease SauiA. and the hydrolysates fractionated on a 0.8% agarose gel. The 3-10 kb fraction of the SauiA was isolated from agarose gels by electroelution.
- This DNA preparation was used to construct a gene library using Stratagene's (LaJoIIa, USA) ZAP Express/Predigested Vector/Gigapack Cloning Kit (product #239615). Ligation, packaging, amplification of library and its conversion to the phagemid form were carried out according to the protocols provided by Stratagene. Plasmid form of the resulting gene library was screened on indicator plates prepared as follows.
- kanamycin 80 ml of sterile LB agar containing 25 mg/1 of kanamycin was placed into each 15 cm Petri dish and allowed to solidify. Subsequently, 10 ml top agar layer was added containing 0.5% DGDG and 0.0005% Safranine O.
- the gene library was plated at a density of approximately 5000 colonies per 15 cm plate. The plates were incubated at 37 0 C for 24 h followed by a four-day incubation at room temperature. A clone forming red halo on indicator plate was selected from the library and purified by cloning on a new indicator plate.
- pBK(L131) The plasmid isolated from this clone (named pBK(L131) ) was used to re-transform E. coli strain XLl -Blue MRF' to kanamycin resistance. All such transformants displayed galactolipase-positive phenotype.
- pBK(L131) contained an approximately 7.5 kb insert. This insert was sequenced.
- One sequenced region (SEQ ID No. 3) was found to contain an open reading frame encoding a protein (SEQ ID No. 4) showing homology to a known lipase from Streptomyces rimosus. This lipase, a member of so- called GDSX family of lipases/esterases/acyl transferases is only known to be able to hydrolyse neutral lipids and artificial lipase substrates.
- the standard pET-system in which the gene is under control of the T7 phage promoter, was used in to express the Ll 31 galactolipase in E. coli.
- the shuttle vector pRX487-5 ( Figure 11) (derived from pIJ4987: Kieser T. et al Practical Streptomyces genetics. The John Innes Foundation, Crowes, Norwich, England (2000)) used for expression of Ll 31 galactolipase in S. lividans combines E. coli plasmid pUC18 and the S. lividans plasmid IJ487.
- the lac promoter of pUC18 is placed upstream of promoter-less kanamycin phosphotransferase gene of pIJ487. Indeed, the plasmid transformed E.
- the vector contains unmodified Ec ⁇ Rl-Xb ⁇ l fragment of the chromosomal DNA of S. thermosacchari comprising the complete coding sequence of the galactolipase gene, about 160 bp of upstream non- coding sequence and 420 bp of downstream non-coding sequence.
- AU transformants displayed similar levels of galactolipase activity as judged by the halo formation on indicator plates.
- S. lividans carrying pRX487-5 was cultivated at 10 1 level and the resulting culture was cloned on indicator plates, all clones appeared to produce equal amounts of galactolipase activity.
- the open reading frame of pBK(L131) encoding presumptive lipolytic enzyme according to the present invention was amplified by PCR using primers oL131-5 (GGTGAATTCATGAGATTGACCCGATCCCTGTCGG, sense primer) and oL131-3 (ACTTCTAGAGCGGCGCCACCGTGACGTACA, anti-sense primer).
- the amplified DNA fragment was digested with EcaRI and Xb ⁇ l and cloned into a B. subtilis - E. coli shuttle vector pGTK44.
- This vector has been constructed by substituting the SaH- EcoRI fragment of plasmid pGTK44 (Povelainen et al., Biochem J. 371, 191-197 (2003)) containing degQ36 promoter with EcoKL-Sall fragment of pGT44 (Kerovuo J. et al. Biotechnology Letters 22, 1311-1317 (2000)).
- Galactolipase activity was detected in E. coli transformed with the resulting plasmid pGTK44(L131) ( Figure 5) using indicator plates. Control transformants (containing parent plasmid pGTK44) were galactolipase-negative. Thus, protein sequence represented by SEQ ID No 4 indeed possesses galactolipase activity.
- the same pair of primers amplified a fragment of the same size (by agarose gel electrophoresis) with chromosomal DNA of Streptomyces sp. Ll 30 further confirming earlier observations about close similarity of the two isolated strains and their galactolipase genes.
- the deduced galactolipase coding region was amplified by PCR using chromosomal DNA of the Streptomyces sp. L131 as template and the two oligonuclotide primers (oL131-51 GGTCATGCTAGCATGAGATTGACCCGATCCCTGTCGG and oL131-31 GCATGGATCCGCGGCGCCACCGTGACGTACA).
- the PCR product was digested with Nhel and Bam ⁇ l and ligated with pETlla (Novagen, USA) vector digested with the same restriction endonucleases.
- the ligation mixture was used to transform the E.coli strain XL-Bluel MRP' and 12 different plasmid clones with restriction patterns corresponding to the structure of pETll(131-51) (Fig. 4) were isolated. Each plasmid clone was used to separately transform the E.coli strain BL21(DE3) and the resulting transformants were grown on LB-ampicilin containing galactolipase activity indicator layer (Example 4). Most clones did express active galactolipase. One clone (pETll(131-51)-12) was selected as a source of recombinant galactolipase for subsequent characterisation.
- the enzyme expressed in E. coli (labelled #236) was analysed and found to have: 0.33 GLU/ml and 0.36 PLU/ml, when analysed using the GLU-7 assay and PLU-7 assay taught herein.
- E.coli BL21(DE3) expressed about 2 mU/ml of galactolipase activity after 40 h cultivation in LB-ampicillin broth (37 0 C 5 200 rpm shaking). Essentially all of the activity was found in the culture broth. No galactolipase activity was detected in E.coli BL21(DE3) transformed with pETl Ia (Novagen, USA) and cultivated under the same conditions.
- Example 6 Expression of the lipolytic enzyme according to the present invention gene from Streptomyces sp. Ll 31 in different hosts.
- this vector can be used to produce Streptomyces Ll 31 lipolytic enzyme according to the present invention in Bacillus. Using this vector is only one of many possible ways to express the L131 lipolytic enzyme according to the present invention in Bacillus.
- the pst promoter employed in pGTK44(L131) may be replaced by any other strong constitutive or regulated promoter active in Bacillus. Many such promoters are known in the art. For example, degQ36 promoter (Yang M et al. J. Bacteriol.
- cdd promoter also known as p43 (Wang PZ, Doi RH. J. Biol. Chem. 259, 8619-8625 (1984), amylase or neutral protease promoters etc.
- pGTK44(L131) and other Bacillus vectors based on pTZ12 replicon (Aoki T. et al., MoI. Gen. Genet. 208, 348-352 (1987)) any other plasmid vector (e.g pUBllO, Gryczan TJ et al. J. Bacteriol. 134, 318-29 (1978) and its derivatives) can be used.
- Streptomyces Ll 31 lipolytic enzyme according to the present invention gene are high-GC Gram positive bacteria, in particular, Streptomyces, (for example, S. lividans, S. coelicolor, S. griseus, S. natalensis, S. rubiginosus, S. olivaceus, S. olivochromogenes, S. violaceoruber),
- Streptomyces for example, S. lividans, S. coelicolor, S. griseus, S. natalensis, S. rubiginosus, S. olivaceus, S. olivochromogenes, S. violaceoruber
- the lipolytic enzyme according to the present invention gene can be introduced under its own promoter on a multi-copy vector (e.g. using pIJllO derivatives such as pIJ486, Ward et al. MoI. Gen. Genet. 203, 468-478 (1986) ) or placed
- Ll 31 lipolytic enzyme gene may be expressed in one of the many suitable fungal species.
- yeasts such as Saccharomyces cerevisiae, Schizosaccharomyces pombe, Pichia pastoris, Hansenula polymorpha are suitable.
- the lipolytic enzyme gene may be placed under control of any of the known strong yeast promoters, such glycolytic promoters (PGK, GDH, ENO etc) phosphate starvation induced promoters such as PHO5, the promoters of ethanol/methanol metabolism such as ADHl promoter in S.cerevisiae or methanol- inducible promoters in H polymorpha or P. pastoris.
- the lipolytic enzyme gene When expressing the lipolytic enzyme gene in any host, construction of a synthetic or semi-synthetic gene encoding the sequence of SEQ ID 4 would be advantageous.
- partly or completely synthetic genes may be designed based on sequences available through homology searches in silico as explained in Example 4. Such sequences, may incorporate a number of useful features that are absent in wild-type lipolytic enzyme genes.
- the codon bias can be corrected to better correspond codon preferences of the expression hosts.
- codon bias correction useful for all hosts is to convert the GTG initiation codon of SEQ ID No 3 into ATG.
- Another typical modification obvious for a man skilled in the art is to exchange the native Streptomyces signal sequence of the Ll 31 lipolytic enzyme with a signal sequence native to or known to be functional in the chosen expression host.
- the recombinant hosts expressing the lipolytic enzyme gene can be, advantageously, mutated to reduce the level of protease activity in the culture broth.
- the cultivation of any of such recombinant hosts can be carried out in the presence of compounds stabilising the enzyme.
- Such compounds may be various proteins (e.g. casein, peptone of serum albumin) or different lipids, lysolipids or detergents (e.g. galactolipids, mono- and diacylglycerols or Triton X-IOO).
- Some lipases may also possess acyl-transferase activity.
- some members of the GDSX family for example, Aeromonas hydrophila acyltransferase (Pl 0480) (taught in copending International Application No. PCT/EB2004/000655) have high acyl-transferase activity.
- Streptomyces Ll 31 lipolytic enzyme may be predicted to have also the acyl-transferase activity as well. This activity can be further enhanced through random mutagenesis /directed evolution. Moreover, since A.
- hydrophila acyl- transferase and Streptomyces Ll 31 lipolytic enzyme share the same overall protein fold, combining the substrate specificity of Streptomyces Ll 31 lipolytic enzyme with high transferase efficiency of the Aeromonas enzyme is possible. This combination may be achieved through the known techniques of targeted mutagenesis/protein design or by gene shuffling.
- the GDSX family of esterase's (Upton C, Buckley JT. Trends Biochem. Sic. 20, 178- 179 (1995), pfam00657.11) is a group of esterases / lipases /acyl transferases sharing a specific sequence motif around the active site serine (GDSX where X is a hydrophobic amino acid residue).
- This group of enzymes is also known as lipase family II (Arpigny JL 5 Jaeger K-E. Biochem. J. 343, 177-183 (1999)).
- this family includes many different types of esterases, lipases and acyl-transferases
- the lipolytic enzyme according to the present invention is a GDSX enzyme.
- the sequences taught in the present invention of the Streptomyces sp. Ll 31 lipolytic enzyme can be used in silico to identify other galactolipases from other species of Streptomyces.
- the sequence is preferably compared with the hidden markov model profiles (BMM profiles) of the pfam database.
- Pfam is a database of protein domain families. Pfam contains curated multiple sequence alignments for each family as well as profile hidden Markov models (profile HMMs) for identifying these domains in new sequences. An introduction to Pfam can be found in Bateman A et al. (2002) Nucleic Acids Res. 30; 276-280. Hidden Markov models are used in a number of databases that aim at classifying proteins, for review see Bateman A and Haft DH (2002) Brief Bioinform 3; 236-245.
- the GDSX motif can be identified using the Hammer software package, the instructions are provided in Durbin R, Eddy S, and Krogh A (1998) Biological sequence analysis; probabilistic models of proteins and nucleic acids. Cambridge University Press, ISBN 0-521-62041-4 and the references therein, and the HMMER2 profile provided within this specification.
- the PFAM database can be accessed, for example, through several servers which are currently located at the following websites. http://www.sanger.ac.uk/Software/Pfam/index.shtml http://pfam.wustl.edu/ http://pfam.jouy.inra.fr/ http://pfam.cgb.ki.se/
- the database offers a search facility where one can enter a protein sequence. Using the default parameters of the database the protein sequence will then be analysed for the presence of Pfam domains.
- the GDSX domain is an established domain in the database and as such its presence in any query sequence will be recognised.
- the database will return the alignment of the Pfam00657 consensus sequence to the query sequence.
- the lipolytic enzyme for use in the compositions/methods of the invention have at least one, preferably more than one, preferably more than two, of the following, a GDSx block, a GANDY block, a HPT block.
- the lipolytic enzyme may have a GDSx block and a GANDY block.
- the enzyme may have a GDSx block and a HPT block.
- the enzyme comprises at least a GDSx block.
- the pfam00657 GDSX domain is a unique identifier which distinguishes proteins possessing this domain from oilier enzymes.
- alternative lipolytic enzymes from other Streptomyces species can be identified by conducting a sequence identity comparison and/or hybridisation with one or more of the PCR sequence fragments shown as SEQ ID No. 1 or SEQ ID No. 2.
- the comparisons may be carried out with fragments comprising over 15 nucleotides of SEQ ID No. 1 or SEQ ID No. 2, preferably with fragments comprising over 20 nucleotides of SEQ ID No. 1 or SEQ ID No. 2.
- the complete sequences shown as SEQ ID No. 1 or SEQ ID No. 2 could be used.
- the hybridisation is carried out at high or very high stringency conditions.
- Nucleotide sequences having at least 80%, preferably at least 85%, at least 90%, at least 95%, at least 97%, at least 98% or at least 99% identity to SEQ ID No. 1 or SEQ ID No. 2 indicate strains of Streptomyces which may be sources of the lipolytic enzyme, i.e. the galactolipase, according to the present invention.
- the sequence of the novel Streptomyces thermosaccha ⁇ L131 offers for the possibility for in silico identification of new family II galactolipases.
- one particular region which may be of particular interest is the GDSX motif.
- the GDSX motif is comprised of four conserved amino acids.
- the serine within the motif is a catalytic serine of the lipid acyltransferase enzyme.
- the serine of the GDSX motif may be in a position corresponding to Ser-16 in Aeromonas hydroph ⁇ la lipolytic enzyme taught in Brumlik & Buckley (Journal of Bacteriology Apr. 1996, Vol. 178, No. 7, p 2060-2064).
- the sequence is preferably compared with the hidden markov model profiles (HMM profiles) of the pfam database.
- HMM profiles hidden markov model profiles
- pfam is a database of protein domain families.
- the pfam database may also be used to identify suitable enzymes from genera other than Streptomyces.
- the GDSX motif can be identified using the Hammer software package, the instructions are provided in Durbin R, Eddy S, and Krogh A (1998) Biological sequence analysis; probabilistic models of proteins and nucleic acids. Cambridge University Press, ISBN 0-521-62041-4 and the references therein, and the HMMER2 profile provided within this specification.
- the lipolytic enzyme in accordance with the present invention comprises the GDSX motif.
- the galactolipase ⁇ ipid acyl-transferase enzyme enzyme of the invention has preferably a GDSx motif, more preferably a GDSY motif.
- the galactolipase/lipid acyl-transferase enzyme enzyme of the invention has preferably a GANDY block, more preferably a GANDY block comprising amino GGNDx, more preferably GGNDA or GGNDL.
- the enzyme of the invention or for use in methods of the invention, has preferable an HTP block.
- the galactolipase/lipid acyl-transferase enzyme of the invention has preferably a GDSY motif and a GANDY block comprising amino GGNDx, preferably GGNDA or GGNDL, and a HTP block (conserved histadine).
- the inventors identified a homologous sequence to Streptomyces Ll 31 which did not comprise a GDSX motif: namely Novosphingobium aromaticivorans (NAL) Novosphingobium ⁇ aromaticivorans ⁇ GDSx 284 aa SEQ ID No. 10
- This enzyme comprises the sequence "GSSF" as opposed to GDSX.
- the GDSx motif may be important when attempting to identify other suitable galactolipases.
- the enzyme from S. rimosus that has been purified and characterised biochemically and shows about 56% sequence homology to Streptomyces L131
- Suitable galactolipase/lipid acyl-transferase enzyme enzymes for use in the methods of the invention may be identified by alignment to the Ll 31 sequence using Align X, the Clustal W pairwise alignment algorithm of VectorNTI using default settings.
- suitable galactolipase for use in the methods of the invention may be identified by alignment to the pfam Pfam00657 consensus sequence (as described in WO04/064987).
- Figure 15 shows an sequence alignment of the Ll 31 and homologues from S.avermitilis and T.fusca.
- Figure 15 illustrates the conservation of the GDSx motif (GDSY in L131 and S.avermitilis and T.fusca), the GANDY box, which is either GGNDA or GGNDL, and the EDPT block (considered to be the conserved catalytic histadine). These three conserved blocks are highlighted in Figure 15.
- Corynebacterium efficiens DSM 44549, Thermobifida fusca DSM 43792 and Streptomyces avermitilis DSM46492 were used for isolating the genes homologous to the galactolipase gene of S. thermosacchari L131.
- DSM Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH
- the strain of Aeromonas salmonicida (DSM 12609) was also used as an expression host.
- thermosacchari L131, Citrobacter freundii P3-42 and Enterobacter nimipressuralis P 1-60 were isolated in our laboratory from natural environment and taxonomically identified by 16S rRNA gene sequencing.
- LB 5 g/1 yeast extract, 10 g/1 tryptone, 10 g/1 NaCl, pH 7.0
- 2xYT lOg/1 NaCl 5 lOg/1 yeast extract, 16 g/1 tryptone
- Nutrient broth 3 g/1 beef extract, 5 g/1 peptone, pH 7.0
- YM-broth 3 g/1 yeast extract, 3 g/1 malt extract, 5 g/1 peptone, 10 g/1 dextrose, pH 7.0
- S. avermitilis Medium 65 (4 g/1 glucose, 4 g/1 tryptone, 10 g/1 malt extract, 2 g/1 CaCO 3 , pH 7.2) was used for T. fusca.
- Standard alkaline lysis procedure combined with Qiagen column purification method was used for plasmid isolation.
- One exception was the preparative isolation of plasmid DNA from Streptomyces. In this case, equilibrium centrifugation in CsCl gradient was used as the final purification step.
- E. coli and C. glutamicum strains were transformed by electroporation using 1 mm cuvettes and the following electroporation parameter settings: 1800V, 25 0 F, 200 ⁇ l B. subtilis BDl 70 was transformed by "Paris" method based on natural competence (Harwood CR. and Cutting S.M., 1990). Streptomyces lividans was transformed by protoplast method (Kieser T. et al. , 2000). DNA was introduced into A. sa ⁇ monicida by conjugation with E. coli using filter mating method of Harayama et al. (1980).
- the lipase gene of Streptomyces avermitilis was amplified by PCR using chromosomal DNA as template and the two oligonucleotide primers oSAL-5 (GGG AATTCCATATGAGACGTTCCCGAATTACG) and oSAL-3 (GCATGGATCCGG TGACCTGTGCGACGG).
- oligonucleotide primers used were oTFL-5 (GGGAATTCCATATGGGCAGCGGACCACGTG) and oTFL-3
- PCR products were digested with Ndel and BamHL and ligated with pETlla (Novagen, USA) vector digested with the same restriction endonucleases.
- Ll 31 galactolipase expression vector for S. lividans was constructed as follows. Plasmid pUC18(L131RX) that contains the 1.37 kb EcoRI-Xbal fragment of the original cloned DNA fragment carrying Ll 31 lipase gene (pBK(L131)) was digested with Ec ⁇ Bl and ligated with EcoKL digested pIJ487 (Kieser et al., 2000). This ligation leads to the formation of the two recombinant plasmids differing in relative orientation of pIJ487 and pUC18(L131RX).
- the transformants were plated on SM plates (Kieser et al., 2000) supplemented with 5 mg/ml of kanamycin and allowed to sporulate. The resulting spores were used for inoculating shake flask and fermentor cultures.
- All expression vectors used in this work are based on the plasmid pCB5 which is a shuttle vector carrying C. glutamicum replicon from plasmid pSRl (Yoshihama et al., 1985) and CoIEl replicon from E. coli.
- the promoter that is used in this vector is derived from the copl gene encoding the major secreted protein of C. glutamicum — PSl.
- Enzymes were expressed from their native genes including unmodified signal peptides, e.g. T.fusca ( Figure 14).
- lipase-producing recombinant S. lividans strains were grown in a medium containing (per litre) 1O g peptone, 5 g yeast extract, 2 g K 2 HPO 4 and 1O g glucose (pH 7.0) supplemented with appropriate antibiotics: thiostreptone was used at 1,2 mg/1, kanamycin at 20 mg/1, chloramphenicol at 1,5 mg/1 and erythromycin at 1,5 mg/1. Spore suspensions produced by growing the transformants on SM plates were used to start the cultivations.
- the initial medium (7 1) contained (per litre): peptone 20 g, yeast extract, 1O g, glucose 20 g and appropriate antibiotics as described above (except for thiostreptone, which was not used in 10 1 cultures).
- the cultivation was conducted at 3O 0 C, constant 10 1/min aeration and 600 rpm stirring rate.
- Inocula 2 x 250 ml per fermentation were grown in 2 1 Erlenmeyer flasks as described in the previous paragraph.
- the fermentation was carried out in batch mode for 18-20 h after which time, a solution containing 30 % glucose and 12,5 % peptone was fed to the fermentor culture at a rate of 0,5 ml/min. Samples (30 ml) of the culture were withdrawn aseptically twice a day.
- the recombinant A. salmonicida strains were cultivated in 2xYT medium supplemented with streptomycin and kanamycin (at 25mg/l). To induce tac promoter, PTG (1-5 mM) or lactose (1-10%) were added to the growth medium.
- the initial medium (7 1) was 2xYT supplemented with 2% glucose, 50 mg/1 of kanamycin and 50 mg/1 of streptomycin and the feeding solution (3 1) contained 25% glucose, 10% tryptone and 5 %yeast extract, 100 mg/1 of both kanamycin and streptomycin. Cultivation was carried out at 10 1/min aeration, 600 rpm stirring rate and 28 0 C. The pH was adjusted to 7.5 by 25% NH 3 and 10% phosphoric acid. The fermentor was inoculated with 0.5 1 of overnight culture of A. salmonicida and grown in batch mode for 24 h. At this point BPTG was added to 5 mM and the feeding was started at a rate of 50 ml/h.
- the initial medium was modified by substituting glucose with lactose.
- Feeding solution was 2 1 of 20% lactose.
- the fermentation temperature was increased to 3O 0 C and the pH of the culture medium decreased to 7.0. Inoculation was done as in the first experiment and the feeding (100 ml/h) was started after 20 h of cultivation in the initial medium
- Lipase activity was measured with a spectrophotometric assay at 30 0 C with ⁇ NPP as substrate, by using 50 mM Tris-Maleate buffer (pH 6.5) with 0,4 % Triton X-100 and 0,1 % gum Arabic.
- the substrate stock solution 100 mM was prepared in dioxane.
- the kinetic measurement was started by addition of enzyme to the reaction mixture.
- the increase in absorption at 410 nm was followed with Spectramax plate reader every 20 s for 20 rain.
- One unit of lipase activity was defined as the amount of enzyme that liberated 1 ⁇ mol of /7-nitrophenol per min.
- the activity toward other p- ⁇ NP esters was measured in the same manner, by using 1 mM each substrate. (Abramic M. et al. (1999))
- Streptomyces Ll 31 galactolipase can be identified, for example, "hypothetical protein” from Thermobifida fusca (ZP 00058717) and “hypothetical protein” from Corynebacterium efficiens (NP 738716).
- Streptomyces L131 galactolipase the genes of Streptomyces avermitilis (SAL), Thermobifida fiisca (TFL), and Corynebacterium efficiens (CEL).
- AU genes were expressed in E. coli by using pET expression system.
- the recombinant E. coli strains were first analysed using DGDG -indicator plates with safranine and the enzymes of S. avermitilis, T. fiisca and C. efficiens were found to have galactolipase activity.
- the enzymes showing galactolipase activity were further examined. Substrate specificities of those galactolipase candidates were studied ( Figure 13). The activity of candidate enzymes towards DGDG, lecithin, olive oil, nitrophenyl butyrate, nitrophenyl decanoate (NP-D) and nitrophenyl pahnitate was tested. The enzymes were found to have very different substrate specificity profiles. Acyl-transferase activity was tested in an assay using NP-D as substrate and quantifying both the release of nitrophenol and free fatty acids by NEFA kit. Preliminary data suggests that at least the enzyme from Thermobifida fiisca has transferase activity towards glycerol and glucose.
- K371 Streptomyces thermosacchari Ll 31 enzyme expressed in S. lividans freeze dried on starch.
- Plant Sterol Generol 122 N from Henkel, Germany
- Lecithin L- ⁇ Phosphatidylcholine 95% Plant (Avanti #441601)
- the phospholipase assay was the same as that used in Example 10.
- HPTLC plate 20 x 10 cm, Merck no. 1.05641. Activated 30 minutes at 160 0 C before use.
- Running buffer 5 P-ether : Methyl-tert-butyl ketone : Acetic acid 70:30:1
- the plate was dried in an oven for 10 minutes at 160°C, cooled, and dipped into 6% cupri acetate in 16% H 3 PO 4 . Dried additionally 10 minutes at 160°C and evaluated directly.
- Figure 16 shows TLC plate (Buffer 4) of reaction products from enzyme treatment of crude soya oil samples according to table 4.
- PC phosphatidylcholine
- PE Phosphatydylethanolamine
- LPC lysophosphatidylcholme
- FIG. 17 shows TLC (Buffer 5) of reaction products from enzyme treatment of crude soya oil samples according to table 4.
- cholesterolester monoglyceride, diglyceride, triglyceride and plant sterol.
- Free fatty acid (FFA) is also indicated
- microorganism identified under I above was accompanied by. a scientific description
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL05773820T PL1776455T3 (en) | 2004-07-16 | 2005-07-18 | Lipolytic enzyme, uses thereof in the food industry |
MX2007000626A MX2007000626A (en) | 2004-07-16 | 2005-07-18 | Protein. |
DK05773820.5T DK1776455T3 (en) | 2004-07-16 | 2005-07-18 | LIPOLYTIC ENZYM, APPLICATIONS THEREOF IN THE FOOD INDUSTRY |
CA002572843A CA2572843A1 (en) | 2004-07-16 | 2005-07-18 | Lipolytic enzyme uses thereof in the food industry |
ES05773820.5T ES2539006T3 (en) | 2004-07-16 | 2005-07-18 | Lipolytic enzyme, uses thereof in the food industry |
AU2005264077A AU2005264077B2 (en) | 2004-07-16 | 2005-07-18 | Lipolytic enzyme uses thereof in the food industry |
BRPI0511835-2A BRPI0511835A (en) | 2004-07-16 | 2005-07-18 | lipolytic enzyme and its uses in the food industry |
EP05773820.5A EP1776455B1 (en) | 2004-07-16 | 2005-07-18 | Lipolytic enzyme, uses thereof in the food industry |
CN2005800240038A CN101052702B (en) | 2004-07-16 | 2005-07-18 | Lipolytic enzyme and application thereof in food industry |
US11/623,607 US7666618B2 (en) | 2004-07-16 | 2007-01-16 | Lipolytic enzyme: uses thereof in the food industry |
US12/697,718 US8889371B2 (en) | 2004-07-16 | 2010-02-01 | Lipolytic enzyme: uses thereof in the food industry |
US12/697,693 US8535900B2 (en) | 2004-07-16 | 2010-02-01 | Lipolytic enzyme uses thereof in the food industry |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0416035.4A GB0416035D0 (en) | 2004-07-16 | 2004-07-16 | Protein |
GB0416035.4 | 2004-07-16 | ||
US59118504P | 2004-07-26 | 2004-07-26 | |
US60/591,185 | 2004-07-26 | ||
GB0513859A GB0513859D0 (en) | 2005-07-07 | 2005-07-07 | Method |
GB0513859.9 | 2005-07-07 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/623,607 Continuation-In-Part US7666618B2 (en) | 2004-07-16 | 2007-01-16 | Lipolytic enzyme: uses thereof in the food industry |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2006008653A2 WO2006008653A2 (en) | 2006-01-26 |
WO2006008653A9 true WO2006008653A9 (en) | 2007-02-22 |
WO2006008653A3 WO2006008653A3 (en) | 2007-03-29 |
Family
ID=38895985
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2005/002823 WO2006008508A1 (en) | 2004-07-16 | 2005-07-18 | Enzymatic oil-degumming method |
PCT/IB2005/002602 WO2006008653A2 (en) | 2004-07-16 | 2005-07-18 | Lipolytic enzyme uses thereof in the food industry |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2005/002823 WO2006008508A1 (en) | 2004-07-16 | 2005-07-18 | Enzymatic oil-degumming method |
Country Status (18)
Country | Link |
---|---|
US (5) | US7666618B2 (en) |
EP (5) | EP1776455B1 (en) |
JP (1) | JP5604032B2 (en) |
KR (1) | KR101226156B1 (en) |
CN (7) | CN101052702B (en) |
AT (1) | ATE514767T1 (en) |
AU (4) | AU2005263954B2 (en) |
BR (2) | BRPI0513438A2 (en) |
CA (2) | CA2571694C (en) |
DK (2) | DK1791933T3 (en) |
EA (1) | EA014985B1 (en) |
ES (1) | ES2539006T3 (en) |
HK (1) | HK1101189A1 (en) |
MX (2) | MX2007000627A (en) |
NZ (1) | NZ551378A (en) |
PL (2) | PL1791933T3 (en) |
PT (1) | PT1791933E (en) |
WO (2) | WO2006008508A1 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7666618B2 (en) | 2004-07-16 | 2010-02-23 | Danisco A/S | Lipolytic enzyme: uses thereof in the food industry |
US7718204B2 (en) | 1998-07-21 | 2010-05-18 | Danisco A/S | Foodstuff |
US7718408B2 (en) | 2003-12-24 | 2010-05-18 | Danisco A/S | Method |
US7807398B2 (en) | 2003-01-17 | 2010-10-05 | Danisco A/S | Method of using lipid acyltransferase |
US7906307B2 (en) | 2003-12-24 | 2011-03-15 | Danisco A/S | Variant lipid acyltransferases and methods of making |
US7955814B2 (en) | 2003-01-17 | 2011-06-07 | Danisco A/S | Method |
US7960150B2 (en) | 2007-01-25 | 2011-06-14 | Danisco A/S | Production of a lipid acyltransferase from transformed Bacillus licheniformis cells |
US8012732B2 (en) | 2004-03-12 | 2011-09-06 | Danisco A/S | Fungal lypolytic and amylase enzyme composition and methods using the same |
US8030044B2 (en) | 2003-12-24 | 2011-10-04 | Danisco A/S | Lipid acyltransferases |
USRE43135E1 (en) | 2001-05-18 | 2012-01-24 | Danisco A/S | Method of improving dough and bread quality |
USRE43341E1 (en) | 1995-06-07 | 2012-05-01 | Danisco A/S | Method of improving the properties of a flour dough, a flour dough improving composition and improved food products |
US8652809B2 (en) | 2007-08-17 | 2014-02-18 | Dupont Nutrition Biosciences Aps | Method for producing ultra-heat treatment milk |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0112226D0 (en) * | 2001-05-18 | 2001-07-11 | Danisco | Method of improving dough and bread quality |
US8012724B2 (en) | 2005-06-13 | 2011-09-06 | Novozymes A/S | Production of degummed fatty acid alkyl esters using both lipase and phospholipase in a reaction mixture |
CN102559627B (en) * | 2007-01-25 | 2014-09-10 | 杜邦营养生物科学有限公司 | Method for utilizing Bacillus licheniformis transformed cell to prepare fatty acyl transferase |
US8338133B2 (en) | 2007-01-30 | 2012-12-25 | Mitsubishi-Kagaku Foods Corporation | DNA encoding glyceroglycolipid lipase |
KR101700711B1 (en) * | 2007-11-21 | 2017-01-31 | 로스킬드 유니베르시테트 | Polypeptides comprising an ice-binding activity |
JP5509094B2 (en) * | 2007-12-21 | 2014-06-04 | デュポン ニュートリション バイオサイエンシーズ エーピーエス | Process for edible oil refining using lipid acyltransferases |
GB0807161D0 (en) * | 2008-04-18 | 2008-05-21 | Danisco | Process |
GB0812559D0 (en) * | 2008-07-09 | 2008-08-13 | Danisco | Method |
GB0905367D0 (en) * | 2009-03-27 | 2009-05-13 | Danisco | Method |
US8945644B2 (en) * | 2009-06-15 | 2015-02-03 | Cavitation Technologies, Inc. | Process to remove impurities from triacylglycerol oil |
EP2281874A1 (en) | 2009-07-31 | 2011-02-09 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Production of ß-Cells |
EP2488638A1 (en) | 2009-10-15 | 2012-08-22 | DuPont Nutrition Biosciences ApS | Lipid acyltransferase proteins and methods of making them |
GB0920089D0 (en) | 2009-11-17 | 2009-12-30 | Danisco | Method |
AR080293A1 (en) | 2010-03-12 | 2012-03-28 | Danisco | REFINING PROCESS OF A VEGETABLE OIL |
GB201007668D0 (en) | 2010-05-07 | 2010-06-23 | Danisco | Method |
EA201291270A1 (en) | 2010-06-17 | 2013-09-30 | ДюПон НЬЮТРИШН БАЙОСАЙЕНСИЗ АпС | METHOD OF MANUFACTURE OF REFINED PLANT OIL USING CHLOROPHYLASE |
CN103459606B (en) | 2011-02-23 | 2017-06-16 | 杜邦营养生物科学有限公司 | Processing method |
AR085251A1 (en) | 2011-02-23 | 2013-09-18 | Danisco | PROCESS TO TREAT VEGETABLE OIL |
KR20230022455A (en) | 2011-07-12 | 2023-02-15 | 임파서블 푸즈 인크. | Methods and compositions for consumables |
US20140220217A1 (en) | 2011-07-12 | 2014-08-07 | Maraxi, Inc. | Method and compositions for consumables |
CN103796530A (en) | 2011-07-12 | 2014-05-14 | 马拉克西公司 | Methods and compositions for consumables |
WO2013104659A2 (en) | 2012-01-13 | 2013-07-18 | Dupont Nutrition Biosciences Aps | Process |
WO2013104660A1 (en) | 2012-01-13 | 2013-07-18 | Dupont Nutrition Biosciences Aps | Process for treating a plant oil comprising hydrolysing chlorophyll or a chlorophyll derivative and involving partial caustic neutralisation |
DK2814924T3 (en) | 2012-02-17 | 2018-07-16 | Clariant Produkte Deutschland | Method for enzymatic slimming |
US10039306B2 (en) | 2012-03-16 | 2018-08-07 | Impossible Foods Inc. | Methods and compositions for consumables |
WO2013160374A1 (en) | 2012-04-27 | 2013-10-31 | Dupont Nutrition Biosciences Aps | Process for refining crude plant oil involving enzymatic hydrolysis and gum recycling |
WO2013160372A1 (en) | 2012-04-27 | 2013-10-31 | Dupont Nutrition Biosciences Aps | Process for treating plant oil involving addition of serial doses of chlorophyll or chlorophyll derivative degrading enzyme |
EP2861701B1 (en) | 2012-06-14 | 2018-12-19 | Bunge Global Innovation, LLC. | Process for production of low saturate oils |
WO2014013538A1 (en) * | 2012-07-17 | 2014-01-23 | 国立大学法人福島大学 | Method for hydrolyzing plasmalogen, method for measuring plasmalogen, phospholipase-containing composition, and method for producing phospholipase |
US9879239B2 (en) | 2012-09-14 | 2018-01-30 | REG Life Sciences, LLC | Enzyme variants with improved ester synthase properties |
CN102907552B (en) * | 2012-10-08 | 2015-08-05 | 云南冷云食品饮料有限责任公司 | A kind of low-fat ice cream and manufacture craft thereof of adding lipolytic enzyme |
JP2016502868A (en) | 2013-01-11 | 2016-02-01 | インポッシブル フーズ インコーポレイテッド | Non-dairy cheese replacement, including coacervate |
ES2662586T3 (en) | 2013-01-11 | 2018-04-09 | Impossible Foods Inc. | Methods and compositions to affect the flavor and aroma profile of consumer products |
EP2971519B1 (en) | 2013-03-15 | 2020-10-28 | United Technologies Corporation | Method for working airfoil clusters of a gas turbine engine |
EP2792735A1 (en) * | 2013-04-16 | 2014-10-22 | Clariant Produkte (Deutschland) GmbH | Method for improving the aqueous enzymatic degumming of vegetable oils |
EP2799531A1 (en) | 2013-05-03 | 2014-11-05 | Clariant Produkte (Deutschland) GmbH | Use of phosphatases for the enzymatic degumming of triglycerides |
CA3185690A1 (en) | 2014-03-31 | 2015-10-08 | Impossible Foods Inc. | Ground meat replicas |
EP3126509A1 (en) | 2014-04-01 | 2017-02-08 | DuPont Nutrition Biosciences ApS | Method for increasing crude palm oil yields |
WO2016011430A1 (en) | 2014-07-18 | 2016-01-21 | REG Life Sciences, LLC | Microbial production of fatty diols |
DK3234083T3 (en) | 2014-12-19 | 2019-04-01 | Dupont Nutrition Biosci Aps | RECOVERY OF OIL FROM PALM SUSPENSION |
US10982171B2 (en) | 2015-07-17 | 2021-04-20 | Keclon Sa | Methods for oil degumming |
BR112019017271A2 (en) | 2017-02-20 | 2020-04-14 | Novozymes As | lipolytic enzyme for use in baking |
CN117343769A (en) | 2018-03-21 | 2024-01-05 | 嘉吉公司 | Dielectric fluid comprising natural bio-derived oil with increased stability |
CN110699178B (en) * | 2019-10-17 | 2022-10-25 | 贵州长顺八妹农副产品开发有限公司 | Method for extracting unsaturated fatty acid from rapeseed oil |
US20230098388A1 (en) | 2020-02-28 | 2023-03-30 | Chr. Hansen A/S | Lipases, compositions, methods and uses thereof |
CN112574975B (en) * | 2020-09-30 | 2022-04-01 | 华南理工大学 | Glyceride lipase mutant G28C-P206C, and coding gene and application thereof |
GB202015772D0 (en) | 2020-10-05 | 2020-11-18 | Univ Newcastle | Pngase enzymes |
CN112450421B (en) * | 2020-10-19 | 2022-09-23 | 杭州师范大学 | Mayonnaise with low greasy taste and preparation method thereof |
KR20220095932A (en) | 2020-12-30 | 2022-07-07 | 주식회사 아데니스 | High hlb lecithin manufacture system and high hlb lecithin manufactured by using the same |
WO2023031266A1 (en) | 2021-09-01 | 2023-03-09 | Chr. Hansen A/S | Yarrowia lipolytica and its use for producing lipases specifically liberating short chain fatty acids |
WO2023092018A1 (en) * | 2021-11-17 | 2023-05-25 | Dupont Nutrition Biosciences Aps | Improved enzymatic modification of galactolipids in food |
Family Cites Families (363)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT110768B (en) | 1927-09-29 | 1928-10-10 | Patiag Patentverwertungs Und I | Wind power machine. |
US2888385A (en) | 1952-11-28 | 1959-05-26 | Grandel Felix | Process of making a preparation containing lipases and oxidases |
US3260606A (en) | 1964-04-29 | 1966-07-12 | Taiyo Food Co Ltd | Enzymatic treatment of egg |
GB1092775A (en) | 1965-07-07 | 1967-11-29 | Knud Aunstrup | Preparation of amyloglucosidase |
DK109695C (en) | 1966-02-09 | 1968-06-10 | Dansk Siemens Aktieselskab | Coupling for automatic transmission of predetermined signal sequences, in particular call numbers in telecommunication systems, as well as code cards for use in the coupling. |
US3368903A (en) | 1966-02-18 | 1968-02-13 | Vanderbilt Co R T | Baked goods dough and method |
CH461935A (en) | 1966-05-03 | 1968-08-31 | Menzi Robert | Manufacturing process of dried pasta |
DE1900959A1 (en) | 1969-01-09 | 1970-08-27 | Unilever Nv | Process for the production of plant phosphatides with universal emulsifying power |
US3634195A (en) | 1969-09-08 | 1972-01-11 | Miles Lab | Production of lipase |
NL154598B (en) | 1970-11-10 | 1977-09-15 | Organon Nv | PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING. |
US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
GB1375783A (en) | 1972-02-04 | 1974-11-27 | ||
GB1442418A (en) | 1972-12-14 | 1976-07-14 | Procter & Gamble | Method of cleansing polyester-containing fabrics |
IL46862A (en) | 1974-04-08 | 1977-12-30 | Baxter Travenol Lab | Lipolytic enzyme flavoring system for fat-containing food |
US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
US3973042A (en) | 1974-05-10 | 1976-08-03 | Cornell Research Foundation, Inc. | Flavor development by microbial lipases in pasteurized milk blue cheese |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
GB1525929A (en) | 1974-11-25 | 1978-09-27 | Unilever Ltd | Stabilised emulsions comprising phospholipoprotein |
GB1577933A (en) | 1976-02-11 | 1980-10-29 | Unilever Ltd | Fat process and composition |
US4160848A (en) | 1977-04-18 | 1979-07-10 | Pennwalt Corporation | Antistaling agent for bakery products |
JPS6049477B2 (en) | 1977-04-19 | 1985-11-01 | 協和醗酵工業株式会社 | Glycerol oxidase and its production method, and method for quantifying glycerol using glycerol oxidase |
US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
JPS5850719B2 (en) | 1978-10-18 | 1983-11-11 | 協和醗酵工業株式会社 | How to quantify triglycerides |
JPS602279Y2 (en) | 1979-03-06 | 1985-01-22 | 日本板硝子株式会社 | Concrete or mortar injection equipment |
US4399218A (en) | 1980-02-05 | 1983-08-16 | Boehringer Mannheim Gmbh | Method and reagent for the determination of glycerin |
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
DE3273290D1 (en) | 1981-05-07 | 1986-10-23 | Unilever Plc | Fat processing |
JPS57189637U (en) | 1981-05-29 | 1982-12-01 | ||
JPS57189638U (en) | 1981-05-29 | 1982-12-01 | ||
JPS58148696U (en) | 1982-03-31 | 1983-10-05 | 三菱重工業株式会社 | fast breeder reactor |
JPS6030488B2 (en) | 1982-11-10 | 1985-07-17 | 協和醗酵工業株式会社 | Fabric improvers and fabrics containing them |
JPS59172485A (en) | 1983-03-18 | 1984-09-29 | Tetsuzo Kato | Production of 2,2-dimethyl-1,3-dioxin-4-one derivative |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
JPS59183881U (en) | 1983-05-25 | 1984-12-07 | 東商株式会社 | Snack drink set storage bag |
DK289083A (en) | 1983-06-23 | 1984-12-24 | Novo Industri As | LIPASE, PROCEDURE FOR PREPARING THEREOF AND ITS APPLICATION |
DK402583D0 (en) | 1983-09-05 | 1983-09-05 | Novo Industri As | PROCEDURE FOR THE MANUFACTURING OF AN IMMOBILIZED LIPASE PREPARATION AND APPLICATION |
DK152763C (en) | 1983-09-05 | 1988-10-24 | Novo Industri As | PROCEDURE FOR PREPARING AN IMMOBILIZED LIPASE PREPARATION |
JPS6078529U (en) | 1983-11-04 | 1985-05-31 | オムロン株式会社 | push button switch |
US4707364A (en) | 1984-01-27 | 1987-11-17 | Miles Laboratories, Inc. | Composition for accelerating cheese aging |
JPS60147578U (en) | 1984-03-13 | 1985-10-01 | トヨタ車体株式会社 | Cover mounting structure for inner panels such as quarter panels |
JPS60258766A (en) | 1984-06-05 | 1985-12-20 | Matsushita Electric Ind Co Ltd | Optical information recording and reproducing device |
US4636468A (en) | 1984-06-25 | 1987-01-13 | Genencor, Inc. | Lipolytic enzyme derived from a aspergillus microorganism having an accelerating effect on cheese flavor development |
CA1262654A (en) | 1984-08-10 | 1989-11-07 | Takaoki Torigoe | Food quality improving agent |
NL8402979A (en) | 1984-09-28 | 1986-04-16 | Tno | METHOD FOR CONTROLLING VEGASOLIC DISEASES IN CROPS, ESPECIALLY DISEASE. |
JPS61181390A (en) | 1985-02-06 | 1986-08-14 | Amano Pharmaceut Co Ltd | Production of glyceride with enzyme |
US4689297A (en) | 1985-03-05 | 1987-08-25 | Miles Laboratories, Inc. | Dust free particulate enzyme formulation |
EP0195311B2 (en) | 1985-03-06 | 1996-01-17 | Yoshikawa Oil & Fat Co., Ltd. | Process for preparing fatty acid esters |
US5219733A (en) | 1985-03-06 | 1993-06-15 | Yoshikawa Oil & Fat Co., Ltd. | Process for preparing fatty acid esters |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
JPS61242542A (en) | 1985-04-22 | 1986-10-28 | Fuji Oil Co Ltd | Production of cheese flavor ingredient |
US5310679A (en) | 1985-05-13 | 1994-05-10 | Artiss Joseph D | Composition for reducing turbidity in samples of biological fluids |
GB8514707D0 (en) | 1985-06-11 | 1985-07-10 | Unilever Plc | Enzymatic detergent composition |
GB8514708D0 (en) | 1985-06-11 | 1985-07-10 | Unilever Plc | Enzymatic detergent composition |
DK154572C (en) | 1985-08-07 | 1989-04-24 | Novo Industri As | ENZYMATIC DETERGENT ADDITIVE, DETERGENT AND METHOD FOR WASHING TEXTILES |
GB8525012D0 (en) | 1985-10-10 | 1985-11-13 | Cpc International Inc | Carbohydrate refining process |
JPH065501Y2 (en) | 1986-01-21 | 1994-02-09 | 丸井産業株式会社 | Metal fitting for stealing |
GB2185990B (en) | 1986-02-05 | 1990-01-24 | Unilever Plc | Margarine fat |
US5536661A (en) | 1987-03-10 | 1996-07-16 | Novo Nordisk A/S | Process for the production of protein products in aspergillus |
US5766912A (en) | 1986-03-17 | 1998-06-16 | Novo Nordisk A/S | Humicola lipase produced in aspergillus |
DK122686D0 (en) | 1986-03-17 | 1986-03-17 | Novo Industri As | PREPARATION OF PROTEINS |
US5874558A (en) | 1986-03-17 | 1999-02-23 | Novo Nordisk | Nucleic acid encoding a recombinant humicola sp. lipase |
JPH0324096Y2 (en) | 1986-04-14 | 1991-05-27 | ||
JPS62262997A (en) | 1986-05-02 | 1987-11-16 | ノボ ノルディスク アクティーゼルスカブ | Production of wax |
JPS62285749A (en) | 1986-06-03 | 1987-12-11 | 日東製粉株式会社 | Production of breads |
JPS6344892A (en) | 1986-08-13 | 1988-02-25 | Kao Corp | Ester exchange reaction of fats and oils |
ATE110768T1 (en) | 1986-08-29 | 1994-09-15 | Novo Nordisk As | ENZYMATIC DETERGENT ADDITIVE. |
DK157560C (en) | 1986-08-29 | 1990-06-11 | Novo Nordisk As | ENZYMATIC DETERGENT ADDITIVE, DETERGENT CONTAINING THE ENZYMATIC DETERGENT ADDITIVE AND PROCEDURE FOR WASHING TEXTILES. |
EP0260573A3 (en) | 1986-09-18 | 1989-03-22 | Lucas Meyer GmbH & Co | Process for preparing a hydrolysed lecithin, and the use of the hydrolysed lecithin |
JP2628667B2 (en) | 1986-10-17 | 1997-07-09 | ノボ ノルディスク アクティーゼルスカブ | Regio-specific lipase |
US5273898A (en) | 1986-10-17 | 1993-12-28 | Noro Nordisk A/S | Thermally stable and positionally non-specific lipase isolated from Candida |
WO1988003365A1 (en) | 1986-11-05 | 1988-05-19 | George Weston Foods Limited | Novel improvers for flour and yeast raised baked goods |
US5108457A (en) | 1986-11-19 | 1992-04-28 | The Clorox Company | Enzymatic peracid bleaching system with modified enzyme |
KR900003014B1 (en) | 1986-12-27 | 1990-05-04 | 도오아 야꾸힌 고오교오 가부시끼가이샤 | Feed additives for fishing |
JPH088866B2 (en) * | 1987-03-10 | 1996-01-31 | 株式会社ヤクルト本社 | Phospholipase D and method for producing the same |
US5219744A (en) | 1987-08-26 | 1993-06-15 | Ajinomoto Co., Inc. | Process for modifying fats and oils |
ES2076939T3 (en) | 1987-08-28 | 1995-11-16 | Novo Nordisk As | RECOMBINANT LUMPY OF HUMICOLA AND PROCEDURE FOR THE PRODUCTION OF RECOMBINANT LIPAS OF HUMICOLA. |
ES2032939T5 (en) | 1987-12-21 | 2000-06-01 | Dsm Nv | A METHOD TO IMPROVE A MASS OF FLOUR. |
DK6488D0 (en) | 1988-01-07 | 1988-01-07 | Novo Industri As | ENZYMES |
WO1989006803A1 (en) | 1988-01-14 | 1989-07-27 | Nordisk Gentofte A/S | Apparatus for determination of the coagulation time of a blood sample |
DK77788A (en) | 1988-02-16 | 1989-08-17 | Novo Industri As | METHOD OF MAKING COCONUT OIL |
JP3079276B2 (en) | 1988-02-28 | 2000-08-21 | 天野製薬株式会社 | Recombinant DNA, Pseudomonas sp. Containing the same, and method for producing lipase using the same |
EP0334462B2 (en) | 1988-03-25 | 2002-04-24 | Genencor International, Inc. | Molecular cloning and expression of genes encoding lipolytic enzymes |
US5232846A (en) | 1988-08-09 | 1993-08-03 | Unitika Ltd. | Method for producing a thermostable lipoprotein lipase from streptomyces |
JP2709736B2 (en) | 1988-08-11 | 1998-02-04 | 昭和産業株式会社 | Oil and fat refining method |
GB8906837D0 (en) | 1989-03-23 | 1989-05-10 | Unilever Plc | Bread improvers |
DE3920561A1 (en) | 1989-06-23 | 1991-01-10 | Knoll Ag | METHOD FOR PREVENTING DIGESTIVE DIFFERENCES IN HERBICINE-EATING ANIMALS |
DE69031710T2 (en) | 1989-07-07 | 1998-03-05 | Unilever Nv | METHOD FOR PRODUCING A PROTEIN BY MEANS OF A MUSHROOM TRANSFORMED BY MULTIPLE COPY INTEGRATION OF AN EXPRESSION VECTOR |
US5213968A (en) | 1989-08-21 | 1993-05-25 | Nestec S.A. | Process for preparing emulsifying agents |
ES2047827T3 (en) | 1989-09-29 | 1994-03-01 | Unilever Nv | FOOD PRODUCTS CONTAINING DEHYDRATED LYSOPHOSPHOLIPOPROTEIN. |
US5677160A (en) | 1989-10-30 | 1997-10-14 | Henkel Corporation | Fat splitting process |
WO1991006661A1 (en) | 1989-11-03 | 1991-05-16 | Opta Food Ingredients, Inc. | Lipase-catalyzed in situ generation of mono- and di-glycerides |
US5288619A (en) | 1989-12-18 | 1994-02-22 | Kraft General Foods, Inc. | Enzymatic method for preparing transesterified oils |
JPH03262492A (en) | 1990-03-06 | 1991-11-22 | P Macneil Gerald | Preparation of monoglyceride |
DK19991D0 (en) | 1991-02-06 | 1991-02-06 | Novo Nordisk As | PROTEIN PREPARATIONS |
KR100225087B1 (en) | 1990-03-23 | 1999-10-15 | 한스 발터라벤 | The expression of phytase in plants |
IL97645A (en) | 1990-03-23 | 1997-03-18 | Gist Brocades Nv | Production of enzymes in seeds and their use |
KR100237148B1 (en) | 1990-05-09 | 2000-01-15 | 한센 핀 베네드 | A cellulase preparation comprising an endoglucanase enzyme |
US5814501A (en) | 1990-06-04 | 1998-09-29 | Genencor International, Inc. | Process for making dust-free enzyme-containing particles from an enzyme-containing fermentation broth |
EP0468731A1 (en) | 1990-07-26 | 1992-01-29 | Oriental Yeast Co., Ltd. | Bread improver and method of producing bread |
JP3006085B2 (en) | 1990-11-30 | 2000-02-07 | オリエンタル酵母工業株式会社 | Bread making improver and bread making method using the same |
US5869438A (en) | 1990-09-13 | 1999-02-09 | Novo Nordisk A/S | Lipase variants |
ATE169671T1 (en) | 1990-09-13 | 1998-08-15 | Novo Nordisk As | LIPASE VARIANTS |
US5892013A (en) | 1990-09-13 | 1999-04-06 | Novo Nordisk A/S | Lipase variants |
CA2058056C (en) | 1990-12-21 | 1996-11-05 | Chiaki Saito | Method of decreasing cholesterol concentration in food |
WO1992014830A1 (en) | 1991-02-13 | 1992-09-03 | Schneider Manfred P | Enzymatic reverse hydrolysis of hydrophilic substrates - preparation of amphiphilic compounds |
PH31068A (en) | 1991-03-07 | 1998-02-05 | Ici Plc | Process for the production of terephthalic acid. |
DE4112440C1 (en) | 1991-04-16 | 1992-10-22 | Diagen Institut Fuer Molekularbiologische Diagnostik Gmbh, 4000 Duesseldorf, De | |
EP0585285B1 (en) | 1991-05-01 | 1998-08-12 | Novo Nordisk A/S | Stabilized enzymes |
AU664827B2 (en) | 1991-05-03 | 1995-12-07 | Raisio Benecol Ltd. | A substance for lowering high cholesterol level in serum and a method for preparing the same |
DE4115938A1 (en) | 1991-05-16 | 1992-11-19 | Metallgesellschaft Ag | ENZYMATIC METHOD FOR REDUCING THE CONTENT OF PHOSPHORUS-CONTAINING COMPONENTS IN VEGETABLE AND ANIMAL OILS |
GB9114734D0 (en) | 1991-07-09 | 1991-08-28 | Univ London | Process for modifying proteins |
CA2077020A1 (en) | 1991-09-03 | 1993-03-04 | Yoshikazu Isono | Process for producing lipoprotein-containing substance having reduced lipid content and food containing substance thus produced |
US5879920A (en) | 1991-10-07 | 1999-03-09 | Genencor International, Inc. | Coated enzyme-containing granule |
DE69207727T2 (en) | 1991-11-11 | 1996-09-19 | Akzo Nobel Nv | Process for the production of salt granules |
MX9206979A (en) | 1991-12-04 | 1993-07-01 | Novo Nordisk As | CLONING METHOD FOR PROTEINS IN YEAST |
PT618807E (en) | 1991-12-20 | 2003-03-31 | Novo Nordisk As | STABILIZED PHARMACEUTICAL FORM COMPREHENDING HUMAN GROWTH HORMONE AND HYSTIDINE |
EP0558112A1 (en) | 1992-02-25 | 1993-09-01 | Unilever N.V. | Enzymic diglyceride removal |
CA2079839A1 (en) | 1992-02-28 | 1993-08-29 | Vincent Destefanis | Calcium peroxide and ascorbic acid containing compositions as replacements for bromate in breadmaking |
GB2267033B (en) | 1992-03-07 | 1996-01-24 | David Garnett | Lysophospholipid Animal Feed Supplement |
DK42092D0 (en) | 1992-03-27 | 1992-03-27 | Novo Nordisk As | |
DK73592D0 (en) | 1992-06-03 | 1992-06-03 | Novo Nordisk As | NEW ENZYM |
EP0575133B2 (en) | 1992-06-16 | 2008-06-18 | Sankyo Lifetech Company Limited | Novel phospholipase A1, process for its preparation and the use thereof |
DK88892D0 (en) | 1992-07-06 | 1992-07-06 | Novo Nordisk As | CONNECTION |
EP0580252A2 (en) | 1992-07-20 | 1994-01-26 | Quest International B.V. | Improvements in or relating to pectin methyl esterase |
ATE135163T1 (en) | 1992-07-27 | 1996-03-15 | Gist Brocades Nv | ENZYME PRODUCT AND METHOD FOR IMPROVING THE QUALITY OF BREAD |
DK104592D0 (en) | 1992-08-21 | 1992-08-21 | Novo Nordisk As | COURSE OF ACTION |
DE69332030T2 (en) | 1992-12-10 | 2002-10-02 | Dsm Nv | PRODUCTION OF HETEROLOGICAL PROTEINS IN FILAMENTOUS FUNGI |
DE69333065T2 (en) | 1992-12-22 | 2004-04-01 | Novozymes A/S | ALKALINE LIPASE |
DK154292D0 (en) | 1992-12-23 | 1992-12-23 | Novo Nordisk As | NEW ENZYM |
JP2937746B2 (en) | 1993-04-25 | 1999-08-23 | 昭和産業株式会社 | Oil and fat refining method |
WO1994026883A2 (en) | 1993-05-18 | 1994-11-24 | Gist-Brocades N.V. | Process for dust-free enzyme manufacture |
ZA943640B (en) | 1993-06-07 | 1995-01-26 | Buckman Labor Inc | Synergistically stabilized liquid enzymatic compositions |
JP2859520B2 (en) | 1993-08-30 | 1999-02-17 | ノボ ノルディスク アクティーゼルスカブ | Lipase, microorganism producing the same, method for producing lipase, and detergent composition containing lipase |
WO1995009909A1 (en) | 1993-10-04 | 1995-04-13 | Novo Nordisk A/S | An enzyme preparation comprising a modified enzyme |
DE69429611D1 (en) | 1993-10-29 | 2002-02-14 | Dsm Nv | Baking improvers |
EP0652289A1 (en) | 1993-11-05 | 1995-05-10 | Unilever Plc | Random interesterification of triglyceride fats |
DE4339556C1 (en) | 1993-11-19 | 1995-02-02 | Metallgesellschaft Ag | Process for degumming vegetable oil by means of enzymes |
EP0659344B1 (en) | 1993-12-24 | 2001-07-04 | Dsm N.V. | Dry yeast compositions |
US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
US6117679A (en) | 1994-02-17 | 2000-09-12 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US5776741A (en) | 1994-02-21 | 1998-07-07 | Novo Nordisk A/S | Method of enzyme immobilization on a particulate silica carrier for synthesis inorganic media |
WO1995022615A1 (en) | 1994-02-22 | 1995-08-24 | Novo Nordisk A/S | A method of preparing a variant of a lipolytic enzyme |
EP0758377A1 (en) | 1994-05-03 | 1997-02-19 | Novo Nordisk A/S | Alkaline glucose oxidase |
US5834280A (en) | 1994-05-03 | 1998-11-10 | Novo Nordisk A/S | Glucose oxidases obtained from a cladosporium |
DE69528524T2 (en) | 1994-05-04 | 2003-06-26 | Genencor Int | LIPASES WITH IMPROVED TENSIOSTABILITY |
US5741665A (en) | 1994-05-10 | 1998-04-21 | University Of Hawaii | Light-regulated promoters for production of heterologous proteins in filamentous fungi |
DE69501228T2 (en) | 1994-05-11 | 1998-05-07 | Amano Pharma Co Ltd | Ascorbate oxidase, gene coding therefor, process for its preparation and reagent composition using the same |
HUT74965A (en) | 1994-06-16 | 1997-03-28 | Firmenich & Cie | Flavouring composition and process |
EP0687414B1 (en) | 1994-06-17 | 2000-11-08 | Dsm N.V. | Bread improving composition |
WO1996009772A2 (en) | 1994-09-21 | 1996-04-04 | Genencor International, Inc. | Defatting starch containing waste products |
JPH10507639A (en) | 1994-10-26 | 1998-07-28 | ノボ ノルディスク アクティーゼルスカブ | Enzyme surfactant composition |
DK0784674T3 (en) | 1994-10-26 | 2002-11-04 | Novozymes As | Hitherto unknown lipolytic enzyme |
WO1996013580A1 (en) | 1994-10-26 | 1996-05-09 | Novo Nordisk A/S | An enzyme with lipolytic activity |
GB2296011B (en) | 1994-12-13 | 1999-06-16 | Solvay | Novel fusarium isolate and lipases, cutinases and enzyme compositions derived therefrom |
US6093562A (en) | 1996-02-05 | 2000-07-25 | Novo Nordisk A/S | Amylase variants |
KR100247233B1 (en) | 1995-02-22 | 2000-06-01 | 마이클 엘. 퓨어링 | Method of reducing sterols and free fatty acid in an animal fat |
JPH08228778A (en) | 1995-02-27 | 1996-09-10 | Showa Denko Kk | New lipase gene and production of lipase using the same |
JP3359777B2 (en) | 1995-03-06 | 2002-12-24 | 日清製粉株式会社 | Instant fried instant noodles and method for producing the same |
WO1996028542A1 (en) | 1995-03-16 | 1996-09-19 | Novo Nordisk A/S | An enzyme with aminopeptidase activity |
US5919746A (en) | 1995-03-30 | 1999-07-06 | Novo Nordisk A/S | Alkaline lipolytic enzyme |
JPH11502411A (en) | 1995-03-30 | 1999-03-02 | ノボ ノルディスク アクティーゼルスカブ | Alkaline lipolytic enzyme |
WO1996032472A1 (en) | 1995-04-11 | 1996-10-17 | Novo Nordisk A/S | Bread-improving additive comprising a xylanolytic enzyme |
US5989599A (en) | 1995-04-24 | 1999-11-23 | Nestec S.A. | Process for the interesterification of phospholipids |
EP0743017B1 (en) | 1995-05-15 | 2004-09-29 | DSM IP Assets B.V. | Application of phospholipases in animal feed |
GB2301103B (en) | 1995-05-23 | 1999-12-22 | Danisco | An enzyme system comprising ferulic acid esterase |
ATE223489T1 (en) | 1995-06-07 | 2002-09-15 | Danisco | RECOMBINANT HEXOSE OXIDASE, METHOD FOR THE PRODUCTION AND USE THEREOF |
GB0112226D0 (en) | 2001-05-18 | 2001-07-11 | Danisco | Method of improving dough and bread quality |
GB0211975D0 (en) * | 2002-05-24 | 2002-07-03 | Danisco | Method |
ES2136409T5 (en) | 1995-06-07 | 2008-12-16 | Danisco A/S | METHOD FOR IMPROVING PROPERTIES OF A FLOUR PASTA. |
US6936289B2 (en) | 1995-06-07 | 2005-08-30 | Danisco A/S | Method of improving the properties of a flour dough, a flour dough improving composition and improved food products |
US6495357B1 (en) | 1995-07-14 | 2002-12-17 | Novozyme A/S | Lipolytic enzymes |
CN1193346A (en) | 1995-07-14 | 1998-09-16 | 诺沃挪第克公司 | Modified enzyme with lipolytic activity |
DE19527274A1 (en) | 1995-07-26 | 1997-01-30 | Metallgesellschaft Ag | Enzymatic process for degumming vegetable oils with Aspergillus phospholipase |
WO1997007205A1 (en) | 1995-08-11 | 1997-02-27 | Novo Nordisk A/S | Method for preparing polypeptide variants |
AU6655196A (en) | 1995-08-11 | 1997-03-12 | Novo Nordisk A/S | Novel lipolytic enzymes |
JP4053595B2 (en) | 1995-09-22 | 2008-02-27 | メディカル・リサーチ・カウンシル | Improvements in or related to mutagenesis of nucleic acids |
FR2739860B1 (en) | 1995-10-17 | 1998-01-02 | Coletica | AMPHIPHILIC COMPLEXES, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THE SAME |
ATE212189T1 (en) | 1995-12-01 | 2002-02-15 | Unilever Nv | MICROWAVE CRISPY BUNS |
US6361974B1 (en) | 1995-12-07 | 2002-03-26 | Diversa Corporation | Exonuclease-mediated nucleic acid reassembly in directed evolution |
US6344328B1 (en) | 1995-12-07 | 2002-02-05 | Diversa Corporation | Method for screening for enzyme activity |
US5756328A (en) | 1995-12-20 | 1998-05-26 | Cornell Research Foundation, Inc. | Acyltransferase and cDNA encoding acyltransferase |
BR9707012A (en) | 1996-01-22 | 1999-07-20 | Novo Nordisk As | Process for the enzymatic hydrolysis of cyclic poly (ethylene terephthalate) oligomers |
WO1997027276A2 (en) | 1996-01-24 | 1997-07-31 | Novo Nordisk Biotech, Inc. | Nucleic acids encoding polypeptides having absidia lipase activity |
US5942430A (en) | 1996-02-16 | 1999-08-24 | Diversa Corporation | Esterases |
US6001586A (en) | 1996-03-29 | 1999-12-14 | Genencor International, Inc. | Compartmentalization method for screening microorganisms |
DE69731195T2 (en) | 1996-04-25 | 2006-03-09 | Novozymes A/S | ALKALINE, LIPOLYTIC ENZYME |
CN1216901A (en) | 1996-05-02 | 1999-05-19 | 诺沃挪第克公司 | Use of dextrin glycosyl transferase in baking |
CN1216902A (en) | 1996-05-02 | 1999-05-19 | 诺沃挪第克公司 | Use of branching enzyme in baking |
DE19620649A1 (en) | 1996-05-22 | 1997-11-27 | Roehm Gmbh | Recombinantly produced Aspergillus lysophospholipase |
CA2256767A1 (en) | 1996-07-01 | 1998-01-08 | Novo Nordisk A/S | Use of a deamidase in baking |
EP0954569A1 (en) | 1996-08-27 | 1999-11-10 | Novo Nordisk A/S | Novel lipolytic enzymes |
CN1231691A (en) | 1996-09-26 | 1999-10-13 | 诺沃挪第克公司 | An enzyme with cyclomaltodextrin glucanotransferase (CGTASE) activity |
CN100467602C (en) | 1996-09-30 | 2009-03-11 | 金克克国际有限公司 | Esterases, DNA encoding therefor and vectors and host cells incorporating same |
JPH10155493A (en) | 1996-10-04 | 1998-06-16 | Sankyo Co Ltd | Gene coding for phospholipase a1 derived from aspergillus |
AU4451897A (en) | 1996-10-11 | 1998-05-11 | Novo Nordisk A/S | Use of a carbohydrate binding domain in baking |
JP3182381B2 (en) | 1996-10-25 | 2001-07-03 | 日清製粉株式会社 | Mechanical noodle making method for noodles |
JP2001504327A (en) | 1996-10-31 | 2001-04-03 | ノボ ノルディスク アクティーゼルスカブ | Novel phospholipase, its production and use |
DE19648343C1 (en) | 1996-11-22 | 1998-02-12 | Roehm Gmbh | Bread or rolls which remain fresh for extended periods |
JP3582265B2 (en) | 1996-11-28 | 2004-10-27 | 味の素株式会社 | Modified flour and processed flour using the same |
US6103505A (en) | 1996-12-09 | 2000-08-15 | Novo Nordisk A/S | Method for reducing phosphorus content of edible oils |
AR010340A1 (en) | 1996-12-09 | 2000-06-07 | Novozymes As | COMPOSITION FOR BAKING, USE OF SUCH COMPOSITION AND USE OF THE POLYPEPTIDE OF SUCH COMPOSITION. |
DE19701348A1 (en) | 1997-01-16 | 1998-07-23 | Roehm Gmbh | Protein with phospholipase activity |
US5821102A (en) | 1997-01-21 | 1998-10-13 | Novo Nordisk Biotech Inc. | Nucleic acids encoding polyeptides having absidia lipase activity |
JP4018769B2 (en) | 1997-01-28 | 2007-12-05 | 日本ケミテック株式会社 | Pancreatic lipase activity inhibitor, functional food and food additive |
DK1015575T3 (en) | 1997-03-18 | 2010-08-23 | Novozymes As | Shuffling of heterologous DNA sequences |
EP1193314B1 (en) | 1997-04-09 | 2004-10-20 | Danisco A/S | Use of lipase for improving doughs and baked products |
GB9709161D0 (en) | 1997-05-06 | 1997-06-25 | Danisco | A process of preparing an anti-oxidant |
ATE236537T1 (en) | 1997-05-16 | 2003-04-15 | Novozymes Biotech Inc | METHOD FOR PRODUCING PROTEIN HYDROLYZATES |
EP0882797B1 (en) | 1997-06-04 | 2003-07-16 | Loders Croklaan B.V. | Preparation of symmetrical triglycerides aba |
RU2140751C1 (en) | 1997-06-11 | 1999-11-10 | Ассоциация "Ассоя" | Food addition for bread and baked goods production |
JP4121186B2 (en) | 1997-06-16 | 2008-07-23 | 株式会社日立製作所 | Ceramic tube inspection method and apparatus |
WO1998059028A1 (en) | 1997-06-23 | 1998-12-30 | The Procter & Gamble Company | Enzymatic detergent compositions |
EP0913468A3 (en) | 1997-07-22 | 2001-06-13 | Dsm N.V. | Bread improving comüposition |
DK0897667T4 (en) | 1997-07-31 | 2009-02-16 | Dsm Ip Assets Bv | Bread enhancing composition |
EP0913092B1 (en) | 1997-10-31 | 2005-05-11 | Amano Enzyme Inc. | Dough composition and preparation thereof |
JP4307713B2 (en) | 1997-12-23 | 2009-08-05 | ノボザイムス アクティーゼルスカブ | Enzyme immobilization method |
US6156548A (en) | 1997-12-23 | 2000-12-05 | Novo Nordisk A/S | Immobilization of enzymes with a fluidized bed for use in an organic medium |
WO1999034011A2 (en) | 1997-12-24 | 1999-07-08 | Genencor International, Inc. | Method of assaying for a preferred enzyme and/or detergent |
GB9801408D0 (en) | 1998-01-22 | 1998-03-18 | Unilever Plc | Frozen food product |
JPH11228986A (en) | 1998-02-10 | 1999-08-24 | Agency Of Ind Science & Technol | Degumming method with phospholipase |
AU3247699A (en) | 1998-02-17 | 1999-09-06 | Novo Nordisk A/S | Lipase variant |
DK1068302T3 (en) | 1998-04-01 | 2005-10-03 | Danisco | Non-maltogenic exoamylases and their use to delay starch retrogradation |
EP1071734A1 (en) | 1998-04-08 | 2001-01-31 | Novozymes A/S | An enzymatic oil-degumming process |
JPH11290078A (en) | 1998-04-09 | 1999-10-26 | Kansai Kagaku Kikai Seisaku Kk | Yeast having lipase on cell surface and its utilization |
US6815190B1 (en) | 1998-04-12 | 2004-11-09 | Novozymes A/S | Cutinase variants |
ES2188143T5 (en) | 1998-04-20 | 2008-11-01 | Novozymes A/S | PREPARATION OF MASS AND BAKED PRODUCTS. |
US6365204B1 (en) | 1998-04-20 | 2002-04-02 | Novozymes | Preparation of dough and baked products |
EP1075527A2 (en) | 1998-04-30 | 2001-02-14 | E.I. Du Pont De Nemours And Company | Triacylglycerol lipases |
US6866837B2 (en) | 1998-06-05 | 2005-03-15 | Mallinckrodt Inc. | Radiolabeled peptides for the diagnosis and treatment of breast and prostate tumors and metastases of such tumors |
US20030074695A1 (en) | 1998-06-24 | 2003-04-17 | Farese Robert V. | Plant diacylglycerol O-acyltransferase and uses thereof |
BR9911800A (en) | 1998-07-02 | 2001-02-28 | Calgene Llc | Diaglycerol glycerol acyl transferase proteins |
SE510497C2 (en) | 1998-07-15 | 1999-05-31 | Biofeed Thailand Co Ltd | Additive for non-ruminant animal or human feed |
WO2000005396A1 (en) | 1998-07-21 | 2000-02-03 | Danisco A/S | Foodstuff |
JP3414652B2 (en) | 1998-10-12 | 2003-06-09 | 敷島製パン株式会社 | Wheat flour baked product, its production method and quality improving agent |
FI115527B (en) | 1998-10-16 | 2005-05-31 | Upm Kymmene Oyj | Use of plant sterol derivatives and products containing them |
CA2354182C (en) | 1998-11-10 | 2014-06-17 | Novo Nordisk Biotech, Inc. | Polypeptides having lysophospholipase activity and nucleic acids encoding same |
RU2235775C2 (en) | 1998-11-27 | 2004-09-10 | Новозимс А/С | Method for preparing lipolytic enzyme variant and lipolytic enzyme (variants) |
DK1131416T3 (en) | 1998-11-27 | 2009-10-26 | Novozymes As | Lipolytic Enzyme Variants |
EP2290058A1 (en) * | 1998-11-27 | 2011-03-02 | Novozymes A/S | Lipolytic enzyme variants |
US7312062B2 (en) | 1998-11-27 | 2007-12-25 | Novozymes A/S | Lipolytic enzyme variants |
JP2000226335A (en) | 1998-12-04 | 2000-08-15 | Amano Pharmaceut Co Ltd | Oral enzyme preparation, enzyme-containing food material and method for internal use of enzyme preparation |
EP1137761B1 (en) | 1998-12-04 | 2007-08-01 | Novozymes A/S | Cutinase variants |
ATE368734T1 (en) | 1998-12-04 | 2007-08-15 | Novozymes As | CUTINASE VARIANTS |
DE69933391T2 (en) | 1998-12-17 | 2007-11-15 | National Research Council Of Canada, Ottawa | DIACYLGLYZERINE ACYLTRANSFERASE GENE FROM PLANTS |
DE60012301D1 (en) | 1999-01-22 | 2004-08-26 | Hunza Di Pistolesi Elvira & C | LIPOPROTEIN COMPLEXES AND COMPOSITIONS CONTAINING THEM |
CA2362546C (en) | 1999-02-16 | 2012-05-15 | Senesco, Inc. | Dna encoding a plant lipase, transgenic plants and a method for controlling senescence in plants |
US6399121B1 (en) | 1999-03-16 | 2002-06-04 | Novozymes A/S | Process for producing cheese |
BRPI0009001B1 (en) | 1999-03-16 | 2017-06-06 | Novozymes As | process for cheese production |
AU4039400A (en) | 1999-03-26 | 2000-10-16 | Diversa Corporation | Exonuclease-mediated nucleic acid reassembly in directed evolution |
AU3418400A (en) | 1999-03-30 | 2000-10-23 | Novozymes A/S | Preparation of dough and baked products |
US6939702B1 (en) | 1999-03-31 | 2005-09-06 | Novozymes A/S | Lipase variant |
WO2000061771A2 (en) | 1999-04-12 | 2000-10-19 | Monsanto Technology Llc | Transgenic plants containing altered levels of sterol compounds and tocopherols |
US6162260A (en) | 1999-05-24 | 2000-12-19 | Novo Nordisk Biochem North America, Inc. | Single-bath biopreparation and dyeing of textiles |
WO2000075295A1 (en) | 1999-06-02 | 2000-12-14 | Novozymes A/S | Chemically modified lipolytic enzyme |
EP1057415A1 (en) | 1999-06-04 | 2000-12-06 | Societe Des Produits Nestle S.A. | Lipase-treated pasta and manufacturing process |
US6254645B1 (en) | 1999-08-20 | 2001-07-03 | Genencor International, Inc. | Enzymatic modification of the surface of a polyester fiber or article |
AU7092900A (en) * | 1999-08-30 | 2001-03-26 | Monsanto Technology Llc | Plant sterol acyltransferases |
US6337187B1 (en) | 1999-11-05 | 2002-01-08 | Millennium Pharmaceuticals, Inc. | 18891, a novel human lipase |
DE10030529A1 (en) * | 1999-09-30 | 2001-04-19 | Biotechnolog Forschung Gmbh | New ester-cleaving enzyme from Thermomonospora fusca, useful for degrading e.g. polyesters, for recycling or surface modification |
ATE494366T1 (en) | 1999-10-14 | 2011-01-15 | Novozymes As | LYSOPHOSHOLIPASE FROM ASPERGILLUS |
US6146869A (en) | 1999-10-21 | 2000-11-14 | Novo Nordisk Biotech, Inc. | Polypeptides having phospholipase B activity and nucleic acids encoding same |
DE19953854C2 (en) | 1999-11-09 | 2002-01-17 | Max Planck Gesellschaft | Process for the production of biopolymers with modified properties |
FI108204B (en) | 1999-11-25 | 2001-11-30 | Kari Johannes Kirjavainen | A film for converting energies |
GB2358784B (en) | 1999-12-03 | 2004-06-30 | Danisco | Method of improving dough and bread quality |
JP2003515332A (en) | 1999-12-03 | 2003-05-07 | ダニスコ アクティーゼルスカブ | How to improve the quality of dough and bread |
GB9928968D0 (en) | 1999-12-07 | 2000-02-02 | Danisco | Enzyme |
AU2367401A (en) | 1999-12-23 | 2001-07-09 | Dsm N.V. | Bread improver comprising bile salt and phospholipase a |
US7078205B2 (en) | 2000-02-17 | 2006-07-18 | Millennium Pharmaceuticals, Inc. | Nucleic acid sequences encoding melanoma associated antigen molecules, aminotransferase molecules, atpase molecules, acyltransferase molecules, pyridoxal-phosphate dependent enzyme molecules and uses therefor |
EP1263941B1 (en) | 2000-03-08 | 2010-12-08 | Danisco A/S | Xylanase variants having altered sensitivity to xylanase inhibitors |
IL135466A (en) | 2000-04-04 | 2006-07-05 | Sobhi Basheer | Process for selective alcoholysis of free sterols in fat-based product with an insoluble matrix-immobilized lipase complex |
EP1591019B2 (en) | 2000-04-14 | 2014-03-12 | Novozymes Inc. | Pectinase treatment of potato products |
DE10018787A1 (en) | 2000-04-15 | 2001-05-03 | Nikolaus Weber | Lipase-catalyzed synthesis of steryl esters, useful e.g. as nutritional supplements to reduce cholesterol levels, by solventless reaction of sterol with carboxylic acid or ester |
EP2258852A1 (en) | 2000-04-28 | 2010-12-08 | Novozymes A/S | Lipolytic enzyme variant |
CA2408406C (en) | 2000-06-02 | 2014-07-29 | Novozymes A/S | Cutinase variants |
US6558715B1 (en) | 2000-10-31 | 2003-05-06 | Novozymes Biotech, Inc. | Methods for using lipases in baking |
US6432898B1 (en) | 2000-10-31 | 2002-08-13 | Novozymes Biotech, Inc. | Polypeptides having lipase activity and nucleic acids encoding same |
EP2119773A1 (en) | 2000-06-26 | 2009-11-18 | Novozymes A/S | Lipolytic enzymes from strains of fusarium and acremonium |
US6509182B2 (en) | 2000-06-26 | 2003-01-21 | Novozymes A/S | Lipolytic enzymes |
US6506588B2 (en) | 2000-06-26 | 2003-01-14 | Novozymes, A/S | Lipolytic enzymes |
US6511837B2 (en) | 2000-06-26 | 2003-01-28 | Novozymes A/S | Lipolytic enzymes |
CA2416191A1 (en) | 2000-07-03 | 2002-01-10 | Mochida Pharmaceutical Co., Ltd. | Novel lipase |
AU7235901A (en) * | 2000-07-06 | 2002-01-21 | Novozymes As | Method of preparing a dough or a baked product made from a dough, with addition of lipolytic enzymes |
AU2001278918A1 (en) | 2000-07-13 | 2002-01-30 | Maxygen, Inc. | Novel lipase genes |
AU2001272373A1 (en) | 2000-07-19 | 2002-01-30 | Novozymes A/S | Cgtase and dna sequence encoding same |
ATE400648T1 (en) | 2000-08-11 | 2008-07-15 | Genencor Int | TRANSFORMATION OF BACILLUS, TRANSFORMANTS AND MUTANT LIBRARIES |
DE10042636C1 (en) * | 2000-08-30 | 2002-04-11 | Epcos Ag | Electrical component and method for its production |
KR100380804B1 (en) * | 2000-09-15 | 2003-04-18 | 한국과학기술원 | Thermostable Phospholipase A1 Mutants and Process for Preparing the Same |
AU2001289588A1 (en) | 2000-09-25 | 2002-04-02 | Novozymes A/S | Phospholipase from zygoascus hellenicus |
US7241463B2 (en) | 2000-09-25 | 2007-07-10 | Novozymes A/S | Methods for processing crustacean material |
DE60119950T2 (en) | 2000-10-12 | 2007-01-11 | Novozymes A/S | PREPARATION OF A BAKED PRODUCT FROM DOUGH |
JP3739274B2 (en) | 2000-10-31 | 2006-01-25 | Kddi株式会社 | Two-system video misalignment correction device |
AU1942202A (en) | 2000-11-17 | 2002-05-27 | Danisco | Method |
US6660491B2 (en) | 2000-11-24 | 2003-12-09 | Ikeda Food Research Co., Ltd. | Process for producing dietary sterol fatty acid esters |
AU2002219020B2 (en) | 2001-01-10 | 2007-05-24 | Novozymes A/S | Thermostable lipolytic enzyme variant |
CA2432329C (en) | 2001-02-07 | 2012-04-10 | Novozymes A/S | Lipase variants |
AU2002233168B2 (en) | 2001-02-21 | 2007-02-15 | Novozymes A/S | Production of starchy food products |
EP1404827A2 (en) | 2001-02-23 | 2004-04-07 | Novozymes A/S | Lipolytic enzyme genes |
ATE362315T1 (en) | 2001-05-18 | 2007-06-15 | Danisco | METHOD FOR PRODUCING DOUGH WITH AN ENZYME |
US6645749B2 (en) | 2001-05-25 | 2003-11-11 | Novozymes A/S | Lipolytic enzyme |
US7630836B2 (en) | 2001-05-30 | 2009-12-08 | The Kitasato Institute | Polynucleotides |
US7419658B2 (en) | 2001-07-09 | 2008-09-02 | Euroscreen S.A. | Isolated ligand of ChemerinR |
ES2345973T3 (en) | 2001-07-11 | 2010-10-07 | Cognis Ip Management Gmbh | LIPASE / ACILTRANSPHERASE FROM CANDIDA PARPSYLOSIS. |
EP1285969B1 (en) | 2001-08-22 | 2006-10-11 | Härting, Thomas Francis | Process for producing sterol or stanol esters by enzymatic transesterification in solvent and water-free media |
DE10142014B4 (en) | 2001-08-28 | 2004-11-11 | Degussa Bioactives Deutschland Gmbh & Co. Kg | Process for the preparation of phosphatidylserine |
GB0121387D0 (en) | 2001-09-04 | 2001-10-24 | Danisco | Modified hydrolases |
AU2002340786A1 (en) | 2001-11-05 | 2003-05-19 | Novozymes A/S | Fat splitting process |
EP1468084A1 (en) | 2002-01-16 | 2004-10-20 | Novozymes A/S | Lipolytic enzyme variants and method for their production |
JP2005517418A (en) | 2002-02-20 | 2005-06-16 | ノボザイムス アクティーゼルスカブ | Cheese manufacturing method |
US7010968B2 (en) | 2002-04-18 | 2006-03-14 | Schrader Bridgeport International, Inc. | Determination of wheel sensor position using a wireless solution |
US7226771B2 (en) | 2002-04-19 | 2007-06-05 | Diversa Corporation | Phospholipases, nucleic acids encoding them and methods for making and using them |
JP2005523019A (en) | 2002-04-19 | 2005-08-04 | ダイヴァーサ コーポレイション | Phospholipases, nucleic acids encoding them, and methods for making and using them |
WO2003097835A2 (en) | 2002-05-16 | 2003-11-27 | Molecular Engines Laboratories | Pharmaceutical compositions for the treatment of cancer |
WO2003097825A2 (en) | 2002-05-21 | 2003-11-27 | Dsm Ip Assets B.V. | Novel phospholipases and uses thereof |
SE0201581D0 (en) | 2002-05-29 | 2002-05-29 | Scandinavian Biotechnology Res | New improved acyltransferase |
AU2003250528A1 (en) * | 2002-05-30 | 2003-12-19 | Council Of Scientific And Industrial Research | Process for the pre-treatment of vegetable oils for physical refining |
WO2004000655A1 (en) | 2002-06-24 | 2003-12-31 | Campbell Soup Company | Dispensing system and method |
US20040203791A1 (en) | 2002-06-26 | 2004-10-14 | Pan Shaowei | Method and apparatus for implementing bi-directional soft handovers between wireless networks via mobile station control |
JP2004024199A (en) * | 2002-06-28 | 2004-01-29 | National Food Research Institute | Protein having mannose isomerase activity and polynucleotide encoding the same |
CN100411525C (en) | 2002-07-03 | 2008-08-20 | 诺维信公司 | Treatment of dough with a lipoxygenase and a lipolytic enzyme |
WO2004018660A2 (en) | 2002-08-19 | 2004-03-04 | Dsm Ip Assets B.V. | Novel lipases and uses thereof |
CA2403025A1 (en) | 2002-10-08 | 2004-04-08 | Cognis Deutschland Gmbh & Co. Kg | Enzymes with lipase/acyltransferase activity |
US6773731B2 (en) * | 2002-10-18 | 2004-08-10 | James S. Campbell | Liquid egg yolk product comprising lysophospholipoprotein |
GB2379165A (en) | 2002-10-22 | 2003-03-05 | Dsm Nv | Animal feed |
JP4300839B2 (en) | 2002-11-14 | 2009-07-22 | セイコーエプソン株式会社 | Image processing apparatus, image processing method, and image processing program |
AU2003302905A1 (en) | 2002-12-11 | 2004-06-30 | Novozymes A/S | Detergent composition comprising endo-glucanase |
AU2003302808B2 (en) | 2002-12-12 | 2009-09-17 | Novozymes A/S | Method of selecting a lipolytic enzyme |
JP2006511725A (en) | 2002-12-23 | 2006-04-06 | ノボザイムス ノース アメリカ,インコーポレイティド | Processing method of polyester cloth |
EP3323887A3 (en) | 2003-01-17 | 2018-09-12 | DuPont Nutrition Biosciences ApS | Method for the in situ production of an emulsifier in a foodstuff |
MXPA05007653A (en) | 2003-01-17 | 2005-09-30 | Danisco | Method. |
US7955814B2 (en) | 2003-01-17 | 2011-06-07 | Danisco A/S | Method |
ES2215482B1 (en) | 2003-03-28 | 2005-12-16 | Consejo Sup. De Invest. Cientificas | MASS IMPROVEMENT COMPOSITION FOR BAKERY AND PASTRY. |
MXPA05011421A (en) | 2003-04-28 | 2006-05-31 | Novozymes As | Phospholipase and method of producing it. |
WO2004111216A2 (en) | 2003-06-19 | 2004-12-23 | Novozymes A/S | Phospholipase variants |
WO2005005977A2 (en) | 2003-06-30 | 2005-01-20 | Applera Corporation | Fluorescent phospholipase assays and compositions |
AU2004257209C1 (en) | 2003-07-07 | 2011-09-08 | Dupont Nutrition Biosciences Aps | Exo-specific amylase polypeptides, nucleic acids encoding those polypeptides and uses thereof |
JP4327536B2 (en) | 2003-09-01 | 2009-09-09 | レシップ株式会社 | Ticket coin slot and ticket coin separator equipped with the same |
DK2664670T3 (en) | 2003-12-03 | 2015-07-27 | Danisco Us Inc | perhydrolase |
US7906307B2 (en) | 2003-12-24 | 2011-03-15 | Danisco A/S | Variant lipid acyltransferases and methods of making |
US7718408B2 (en) * | 2003-12-24 | 2010-05-18 | Danisco A/S | Method |
JP5697294B2 (en) * | 2003-12-24 | 2015-04-08 | デュポン ニュートリション バイオサイエンシーズ エーピーエス | Glycolipid acyltransferase mutant and method for producing the same |
DK1704240T3 (en) | 2003-12-24 | 2008-02-25 | Danisco | Enzymatic treatment of oils |
GB0716126D0 (en) | 2007-08-17 | 2007-09-26 | Danisco | Process |
WO2005080540A1 (en) | 2004-02-24 | 2005-09-01 | Novozymes A/S | Enzyme stabilization in liquid detergents |
GB0405637D0 (en) | 2004-03-12 | 2004-04-21 | Danisco | Protein |
JP2007532117A (en) | 2004-04-08 | 2007-11-15 | ジェネンコー・インターナショナル・インク | α-amylase mutant |
BRPI0513438A2 (en) * | 2004-07-16 | 2011-01-04 | Danisco | enzymatic method for oil degumming |
DE602004002866T2 (en) | 2004-08-06 | 2007-05-24 | De Smet Engineering N.V. | Process for recovering oil |
WO2006031699A2 (en) | 2004-09-10 | 2006-03-23 | Diversa Corporation | Compositions and methods for making and modifying oils |
US7811979B2 (en) | 2004-09-21 | 2010-10-12 | Novozymes A/S | Subtilases |
EP2298872A3 (en) | 2004-09-30 | 2011-08-10 | Novozymes A/S | Polypeptides having lipase activity and polynucleotides encoding same |
ES2349125T3 (en) | 2004-10-25 | 2010-12-28 | Nestec S.A. | MODIFIED COCOA BASED PRODUCT AND PROCESS FOR MANUFACTURING. |
WO2006066590A1 (en) | 2004-12-21 | 2006-06-29 | Novozymes A/S | Method for producing fractions of a milk composition |
DE102005039836A1 (en) | 2005-08-23 | 2007-03-01 | Cognis Ip Management Gmbh | Sterolesterpulver |
EP1788080A1 (en) | 2005-11-22 | 2007-05-23 | Süd-Chemie Ag | Use of a thermostable phospholipase in the degumming of an oil or fat, and a method for obtaining a thermostable phopholipase |
EP1876222A1 (en) | 2006-07-06 | 2008-01-09 | Cognis IP Management GmbH | Process for production of fatty acids, fatty acid esters and sterolesters from soapstock |
AR062947A1 (en) | 2006-09-21 | 2008-12-17 | Verenium Corp | NUCLEIC ACID PHOSPHOLIPASSES CODING THEM AND METHODS TO PREPARE AND USE THEM |
MX2009008021A (en) | 2007-01-25 | 2009-08-07 | Danisco | Production of a lipid acyltransferase from transformed bacillus licheniformis cells. |
ES2523300T3 (en) | 2007-01-30 | 2014-11-24 | Bunge Oils, Inc | Enzymatic degumming using a mixture of PLA and PLC phospholipases |
WO2009002480A2 (en) | 2007-06-26 | 2008-12-31 | Danisco Us, Inc., Genencor Division | Acyl transferase having altered substrate specificity |
CN101200754B (en) | 2007-12-07 | 2010-06-02 | 中国农业科学院油料作物研究所 | Method for producing plant sterol ester by immobilized whole-cell enzyme catalysis in solvent-free system |
JP5509094B2 (en) | 2007-12-21 | 2014-06-04 | デュポン ニュートリション バイオサイエンシーズ エーピーエス | Process for edible oil refining using lipid acyltransferases |
JP5211852B2 (en) | 2008-05-23 | 2013-06-12 | 株式会社Ihi | Pressurized levitating apparatus and pressurized levitating method |
-
2005
- 2005-07-18 BR BRPI0513438-2A patent/BRPI0513438A2/en not_active Application Discontinuation
- 2005-07-18 CN CN2005800240038A patent/CN101052702B/en not_active Expired - Fee Related
- 2005-07-18 MX MX2007000627A patent/MX2007000627A/en active IP Right Grant
- 2005-07-18 CN CN201110462189.2A patent/CN102533440B/en not_active Expired - Fee Related
- 2005-07-18 EP EP05773820.5A patent/EP1776455B1/en not_active Not-in-force
- 2005-07-18 JP JP2007520902A patent/JP5604032B2/en not_active Expired - Fee Related
- 2005-07-18 BR BRPI0511835-2A patent/BRPI0511835A/en not_active Application Discontinuation
- 2005-07-18 CN CN201010151132.6A patent/CN102154391B/en not_active Expired - Fee Related
- 2005-07-18 MX MX2007000626A patent/MX2007000626A/en active IP Right Grant
- 2005-07-18 CN CN2012102580799A patent/CN102876739A/en active Pending
- 2005-07-18 EA EA200700040A patent/EA014985B1/en not_active IP Right Cessation
- 2005-07-18 CA CA2571694A patent/CA2571694C/en not_active Expired - Fee Related
- 2005-07-18 EP EP10174040A patent/EP2267107A3/en not_active Withdrawn
- 2005-07-18 AU AU2005263954A patent/AU2005263954B2/en not_active Ceased
- 2005-07-18 CN CNA2005800239825A patent/CN1984982A/en active Pending
- 2005-07-18 NZ NZ551378A patent/NZ551378A/en not_active IP Right Cessation
- 2005-07-18 WO PCT/GB2005/002823 patent/WO2006008508A1/en active Application Filing
- 2005-07-18 AT AT05761577T patent/ATE514767T1/en active
- 2005-07-18 EP EP10175653A patent/EP2275522A3/en not_active Withdrawn
- 2005-07-18 EP EP05761577A patent/EP1791933B1/en not_active Not-in-force
- 2005-07-18 AU AU2005264077A patent/AU2005264077B2/en not_active Ceased
- 2005-07-18 EP EP10174207A patent/EP2267108A1/en not_active Withdrawn
- 2005-07-18 DK DK05761577.5T patent/DK1791933T3/en active
- 2005-07-18 PL PL05761577T patent/PL1791933T3/en unknown
- 2005-07-18 PL PL05773820T patent/PL1776455T3/en unknown
- 2005-07-18 ES ES05773820.5T patent/ES2539006T3/en active Active
- 2005-07-18 CA CA002572843A patent/CA2572843A1/en not_active Abandoned
- 2005-07-18 WO PCT/IB2005/002602 patent/WO2006008653A2/en active Application Filing
- 2005-07-18 KR KR1020067024273A patent/KR101226156B1/en not_active IP Right Cessation
- 2005-07-18 DK DK05773820.5T patent/DK1776455T3/en active
- 2005-07-18 PT PT05761577T patent/PT1791933E/en unknown
- 2005-07-18 CN CN2011101083351A patent/CN102277231A/en active Pending
- 2005-07-18 CN CN201010151115A patent/CN101818177A/en active Pending
-
2007
- 2007-01-16 US US11/623,607 patent/US7666618B2/en not_active Expired - Fee Related
- 2007-01-16 US US11/623,689 patent/US8192782B2/en not_active Expired - Fee Related
- 2007-08-24 HK HK07109224.2A patent/HK1101189A1/en not_active IP Right Cessation
-
2010
- 2010-02-01 US US12/697,693 patent/US8535900B2/en not_active Expired - Fee Related
- 2010-02-01 US US12/697,718 patent/US8889371B2/en not_active Expired - Fee Related
- 2010-08-30 AU AU2010214723A patent/AU2010214723B2/en not_active Ceased
- 2010-08-30 AU AU2010214721A patent/AU2010214721B2/en not_active Ceased
-
2011
- 2011-06-29 US US13/172,679 patent/US8927036B2/en not_active Expired - Fee Related
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE43341E1 (en) | 1995-06-07 | 2012-05-01 | Danisco A/S | Method of improving the properties of a flour dough, a flour dough improving composition and improved food products |
US7972638B2 (en) | 1998-07-21 | 2011-07-05 | Danisco A/S | Foodstuff |
US7718204B2 (en) | 1998-07-21 | 2010-05-18 | Danisco A/S | Foodstuff |
US7781001B2 (en) | 1998-07-21 | 2010-08-24 | Danisco A/S | Foodstuff |
US8163315B2 (en) | 1998-07-21 | 2012-04-24 | Danisco A/S | Foodstuff |
USRE43135E1 (en) | 2001-05-18 | 2012-01-24 | Danisco A/S | Method of improving dough and bread quality |
US8278062B2 (en) | 2003-01-14 | 2012-10-02 | Dupont Nutrition Biosciences Aps | Method of using lipid acyltransferase |
US8003095B2 (en) | 2003-01-17 | 2011-08-23 | Danisco A/S | Method of using lipid acyltransferase |
US7955813B2 (en) | 2003-01-17 | 2011-06-07 | Danisco, A/S | Method of using lipid acyltransferase |
US7955814B2 (en) | 2003-01-17 | 2011-06-07 | Danisco A/S | Method |
US7807398B2 (en) | 2003-01-17 | 2010-10-05 | Danisco A/S | Method of using lipid acyltransferase |
US7718408B2 (en) | 2003-12-24 | 2010-05-18 | Danisco A/S | Method |
US8030044B2 (en) | 2003-12-24 | 2011-10-04 | Danisco A/S | Lipid acyltransferases |
US7906307B2 (en) | 2003-12-24 | 2011-03-15 | Danisco A/S | Variant lipid acyltransferases and methods of making |
US8440435B2 (en) | 2003-12-24 | 2013-05-14 | Dupont Nutrition Biosciences Aps | Method for reducing 1,2-diglyceride content of an edible oil |
US8012732B2 (en) | 2004-03-12 | 2011-09-06 | Danisco A/S | Fungal lypolytic and amylase enzyme composition and methods using the same |
US7666618B2 (en) | 2004-07-16 | 2010-02-23 | Danisco A/S | Lipolytic enzyme: uses thereof in the food industry |
US8192782B2 (en) | 2004-07-16 | 2012-06-05 | Danisco A/S | Enzymatic oil-degumming method |
US8535900B2 (en) | 2004-07-16 | 2013-09-17 | Dupont Nutrition Biosciences Aps | Lipolytic enzyme uses thereof in the food industry |
US8889371B2 (en) | 2004-07-16 | 2014-11-18 | Dupont Nutrition Biosciences Aps | Lipolytic enzyme: uses thereof in the food industry |
US7960150B2 (en) | 2007-01-25 | 2011-06-14 | Danisco A/S | Production of a lipid acyltransferase from transformed Bacillus licheniformis cells |
US8652809B2 (en) | 2007-08-17 | 2014-02-18 | Dupont Nutrition Biosciences Aps | Method for producing ultra-heat treatment milk |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2005264077B2 (en) | Lipolytic enzyme uses thereof in the food industry | |
DK2119771T3 (en) | PROTEINS | |
JP4804340B2 (en) | Use of lipid acyltransferases | |
CA2695562C (en) | Lipid acyltransferase | |
JP2007061100A (en) | Method | |
JP2007516717A6 (en) | protein | |
RU2538144C2 (en) | Lipollytic enzymes, their use in application of food products | |
JP2010142243A (en) | Lipid acyl group transferase variant improved in phospholipid transferase activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005264077 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005773820 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006/10468 Country of ref document: ZA Ref document number: 200610468 Country of ref document: ZA |
|
ENP | Entry into the national phase |
Ref document number: 2005264077 Country of ref document: AU Date of ref document: 20050718 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005264077 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2572843 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11623607 Country of ref document: US Ref document number: MX/a/2007/000626 Country of ref document: MX Ref document number: 200580024003.8 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 675/CHENP/2007 Country of ref document: IN Ref document number: 2007105739 Country of ref document: RU |
|
WWP | Wipo information: published in national office |
Ref document number: 2005773820 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0511835 Country of ref document: BR |
|
WWP | Wipo information: published in national office |
Ref document number: 11623607 Country of ref document: US |